[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 216
1. Roberson JR, Spraker HL, Shelso J, Zhou Y, Inaba H, Metzger ML, Rubnitz JE, Ribeiro RC, Sandlund JT, Jeha S, Pui CH, Howard SC: Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. Leukemia; 2009 Feb;23(2):245-50
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia.
  • Hyperglycemia adversely affects outcome in adult patients with acute lymphoblastic leukemia (ALL), but its impact on children with this disease is unknown.
  • We evaluated the relationship between hyperglycemia during remission induction therapy and clinical outcomes among pediatric patients with ALL.
  • We reviewed the records of patients enrolled on four consecutive ALL protocols (Total Therapy protocols XIIIA, XIIIB, XIV and XV) at St Jude Children's Research Hospital from 1991 to 2007 and identified those who experienced hyperglycemia (glucose >or=200 mg per 100 ml) during remission induction.
  • Complete remission (CR) rates at the end of induction, event-free survival (EFS), overall survival (OS), cumulative incidence of relapse and occurrence of infections were compared between those who did and did not experience hyperglycemia.
  • Of 871 patients analyzed, 141 (16%) experienced hyperglycemia during remission induction.
  • Pediatric patients with or without hyperglycemia during remission induction for ALL have similar clinical outcome.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pract. 2004 Mar-Apr;10 Suppl 2:46-52 [15251640.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1677-84 [15378506.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Pediatrics. 1972 Apr;49(4):590-5 [4501679.001]
  • [Cites] Cancer Res. 1973 Jan;33(1):1-4 [4565907.001]
  • [Cites] Diabetes. 1974 Jan;23(1):9-15 [4809622.001]
  • [Cites] Diabetologia. 1978 Aug;15(2):113-6 [359390.001]
  • [Cites] Diabetes. 1980 Jul;29(7):528-31 [6991339.001]
  • [Cites] Metabolism. 1980 Dec;29(12):1262-6 [7005618.001]
  • [Cites] J Pediatr. 1981 Jul;99(1):46-50 [6454771.001]
  • [Cites] Horm Metab Res. 1984 Dec;16 Suppl 1:92-6 [6398268.001]
  • [Cites] J Trauma. 1990 Jul;30(7):830-2; discussion 832-3 [2380999.001]
  • [Cites] Indian J Cancer. 1993 Jun;30(2):72-6 [8225380.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1993 Jun;51(6):457-61 [8281494.001]
  • [Cites] FEMS Immunol Med Microbiol. 1993 Dec;7(4):315-20 [8136782.001]
  • [Cites] Arch Dis Child. 1996 Feb;74(2):101-7 [8660070.001]
  • [Cites] Horm Metab Res. 1996 Jun;28(6):267-70 [8811326.001]
  • [Cites] J Appl Physiol (1985). 1997 Nov;83(5):1566-74 [9375321.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] J Pediatr. 2005 Jan;146(1):30-4 [15644818.001]
  • [Cites] Leukemia. 2005 Apr;19(4):537-44 [15690069.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):960-3 [15700246.001]
  • [Cites] Acta Paediatr. 2006 Apr;95(4):486-93 [16720499.001]
  • [Cites] Pediatrics. 2006 Jul;118(1):173-9 [16818563.001]
  • [Cites] Pediatr Crit Care Med. 2006 Jul;7(4):351-5 [16738506.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):259-63 [17635005.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1207-12 [18266226.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1932-9 [18421047.001]
  • [Cites] Helv Paediatr Acta. 1973 Oct;28(4):365-9 [4519479.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Trauma. 2001 Sep;51(3):540-4 [11535907.001]
  • [Cites] J Biol Chem. 2001 Oct 12;276(41):37747-53 [11489902.001]
  • [Cites] N Engl J Med. 2001 Nov 8;345(19):1359-67 [11794168.001]
  • [Cites] Pancreas. 2002 Jan;24(1):26-33 [11741179.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):978-82 [11889147.001]
  • [Cites] Childs Nerv Syst. 2002 Apr;18(3-4):129-36 [11981619.001]
  • [Cites] Blood Rev. 2002 Dec;16(4):225-43 [12350366.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3084-91 [12915598.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2041-7 [14559958.001]
  • [Cites] J Trauma. 2003 Dec;55(6):1035-8 [14676647.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1179-85 [15022284.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] J Pediatr Surg. 2004 Jun;39(6):898-901; discussion 898-901 [15185221.001]
  • [Cites] Pediatr Crit Care Med. 2004 Jul;5(4):329-36 [15215001.001]
  • (PMID = 18923438.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / U01 GM061393-09; United States / NCI NIH HHS / CA / CA-78224; United States / NCI NIH HHS / CA / R01 CA078224-09; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / CA-60419; United States / NCI NIH HHS / CA / R37 CA036401-21; United States / NCI NIH HHS / CA / R01 CA060419-13; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; None / None / / R01 CA051001-15; United States / NCI NIH HHS / CA / CA-36401; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / R01 CA051001-15; United States / NCI NIH HHS / CA / P30 CA021765; None / None / / R01 CA078224-09; None / None / / P30 CA021765-30; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA036401; None / None / / R01 CA060419-13; United States / NCI NIH HHS / CA / P30 CA021765-30; United States / NIGMS NIH HHS / GM / GM-61393; United States / NCI NIH HHS / CA / U01 CA060419; United States / NCI NIH HHS / CA / CA036401-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS104861; NLM/ PMC2706830
  •  go-up   go-down


2. Marks DI, Pérez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ: Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood; 2008 Jul 15;112(2):426-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission.
  • We report the retrospective outcomes of unrelated donor (URD) transplants in 169 patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) who received transplants between 1995 and 2004.
  • A total of 50% had a white blood cell count (WBC) more than 30 x 10(9)/L, 18% extramedullary disease, 42% achieved CR more than 8 weeks from diagnosis, 25% had adverse cytogenetics, and 19% had T-cell leukemia.
  • At 54-month median follow-up, incidences of acute grade 2-IV, III to IV, and chronic graft-versus-host disease were 50%, 25%, and 43%, respectively.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2005 Mar;35(6):549-56 [15756282.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58 [18541193.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1572-7 [11238093.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Dec;14(4):793-805 [11924922.001]
  • [Cites] Haematologica. 2003 May;88(5):555-60 [12745275.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1619-28 [7632972.001]
  • [Cites] Bone Marrow Transplant. 1998 Jan;21(2):153-8 [9489632.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):931-6 [9508175.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2236-46 [10498594.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3028-37 [15256423.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):683-9 [16113673.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):155-63 [16284608.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2657-63 [16703597.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5695-702 [17116940.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Blood. 2007 Jul 1;110(1):409-17 [17374741.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [CommentIn] Blood. 2008 Jul 15;112(2):212 [18606879.001]
  • [CommentIn] Blood. 2008 Jul 15;112(2):447-8; author reply 448-9 [18606892.001]
  • (PMID = 18398065.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2442751
  •  go-up   go-down


3. Cornelissen JJ, van der Holt B, Verhoef GE, van't Veer MB, van Oers MH, Schouten HC, Ossenkoppele G, Sonneveld P, Maertens J, van Marwijk Kooy M, Schaafsma MR, Wijermans PW, Biesma DH, Wittebol S, Voogt PJ, Baars JW, Zachée P, Verdonck LF, Löwenberg B, Dekker AW, Dutch-Belgian HOVON Cooperative Group: Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood; 2009 Feb 5;113(6):1375-82
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.
  • While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hematopoietic stem cell transplantation (allo-SCT) is still disputed in adult patients with standard-risk ALL.
  • We evaluated outcome of patients with ALL in first complete remission (CR1), according to a sibling donor versus no-donor comparison.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Autologous / methods. Transplantation, Homologous / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Living Donors. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Prospective Studies. Remission Induction. Risk Factors. Siblings. Transplantation Conditioning. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18988865.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Investigator] Cornelissen JJ; van der Holt B; Verhoef GE; van't Veer MB; van Oers MH; Schouten HC; Ossenkoppele G; Sonneveld P; Maertens J; van Marwijk Kooy M; Schaafsma MR; Wijermans PW; Biesma DH; Wittebol S; Voogt PJ; Baars JW; Zachée P; Verdonck LF; Löwenberg B; Dekker AW
  •  go-up   go-down


Advertisement
4. Kikuchi M, Tanaka J, Kondo T, Hashino S, Kasai M, Kurosawa M, Iwasaki H, Morioka M, Kawamura T, Masauzi N, Fukuhara T, Kakinoki Y, Kobayashi H, Noto S, Asaka M, Imamura M: Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia. Int J Hematol; 2010 Oct;92(3):481-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia.
  • Monitoring minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) is a useful way for assessing treatment response and relapse.
  • We studied the value of MRD and showed a correlation with relapse for 34 adult patients with ALL.
  • The overall survival (OS) rate (45.0%) and relapse-free survival (RFS) rate (40.0%) at 2 years in complete remission (CR) patients with MRD level ≥ 10⁻³ (n = 12) were significantly lower than those in CR patients with MRD level <10(-3) (n = 15) (OS rate 79.0%, RFS rate 79.4%) (log-rank test, P = 0.017 and 0.0007).
  • MRD analysis on day 100 is important for treatment decision in adult ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Flow Cytometry. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction. Prognosis. Recurrence. Remission Induction. Stem Cell Transplantation. Survival Analysis. Transplantation, Homologous. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20830615.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Fu MW, Mi YC, Qiu LG, Yu WJ, Lin D, Bian SG, Wang JX: [Analysis of chemotherapeutic results and prognostic factors of adult acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2008 Jul;29(7):435-40
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of chemotherapeutic results and prognostic factors of adult acute lymphoblastic leukemia].
  • OBJECTIVE: To explore the clinical characteristics of adult acute lymphoblastic leukemia (ALL), compare the efficacy of different induction regimens and analyze the prognostic factors.
  • METHODS: Data of 149 adult ALL patients hospitalized in our institute between June 1998 and December 2005 were retrospectively reviewed.
  • 2) 149 patients completed the VDCP, VDLP or VDCLP induction therapies (at least 4 weeks treatment for each), 140 (93.7%) of them achieved complete remission (CR) with the first course CR rates of 80.8%, 92.3% and 81.4% , respectively (P=0.618).
  • CONCLUSIONS: Most adult ALL patients are B-ALL and karyotype have more changed.
  • Age and WBC at diagnosis, presence of t(9;22) (q34;q11) and the courses of post-remission treatment are important prognostic factors.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035173.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


6. Zheng C, Liu X, Wu J, Cai X, Zhu W, Sun Z: Which steroids should we choose for the treatment of adult acute lymphoblastic leukemia? Am J Hematol; 2010 Oct;85(10):817-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Which steroids should we choose for the treatment of adult acute lymphoblastic leukemia?
  • Corticosteroids are essential and one of the mainstays in the treatment of acute lymphoblastic leukemia (ALL).
  • However, the data were limited in adult ALL.
  • Recently, Labar et al. [2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.
  • In Labar’s observation, about 70% of adult patients were high risk (HR) ALL.
  • In our study, we also evaluate the role of DXM compared with PDN during induction or subsequent phases of therapy in adult ALL with emphasis on SR group.
  • [MeSH-major] Dexamethasone. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisolone
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infection / epidemiology. Male. Middle Aged. Remission Induction. Risk. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20815080.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


7. Gregorj C, Ricciardi MR, Petrucci MT, Scerpa MC, De Cave F, Fazi P, Vignetti M, Vitale A, Mancini M, Cimino G, Palmieri S, Di Raimondo F, Specchia G, Fabbiano F, Cantore N, Mosna F, Camera A, Luppi M, Annino L, Miraglia E, Fioritoni G, Ronco F, Meloni G, Mandelli F, Andreeff M, Milella M, Foà R, Tafuri A, GIMEMA Acute Leukemia Working Party: ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood; 2007 Jun 15;109(12):5473-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.
  • The aim of this study was to assess the expression and clinical role of p-ERK1/2 in adult acute lymphoblastic leukemia (ALL).
  • In 131 primary samples from adult de novo ALL patients enrolled in the Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA) Leucemia Acute Linfoide (LAL) 2000 protocol and evaluated by flow cytometry, constitutive ERK1/2 activation was found in 34.5% of cases; these results were significantly associated with higher white blood cell (WBC) values (P=.013).
  • In a multivariate analysis, p-ERK1/2 expression was an independent predictor of complete remission achievement (P=.027).
  • Effective approaches toward MEK inhibition need to be explored in order to evaluate whether this may represent a new therapeutic strategy for adult ALL patients.
  • [MeSH-major] Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Predictive Value of Tests
  • [MeSH-minor] Adolescent. Adult. Female. Flow Cytometry. Humans. Leukocytes. Male. Middle Aged. Phosphorylation. Prognosis. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17351113.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


8. Baldus CD, Thibaut J, Goekbuget N, Stroux A, Schlee C, Mossner M, Burmeister T, Schwartz S, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK: Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica; 2009 Oct;94(10):1383-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.
  • BACKGROUND: NOTCH1 mutations have been associated with a favorable outcome in pediatric acute T-lymphoblastic leukemia.
  • However, the results of studies on the prognostic significance of NOTCH1 mutations in adult T-lymphoblastic leukemia remain controversial.
  • DESIGN AND METHODS: Here we have investigated the prognostic impact of mutations in the NOTCH1 pathway, in particular, the NOTCH1 and FBXW7 genes, in a large cohort of adult patients with T-lymphoblastic leukemia (n=126).
  • In the overall cohort, no significant differences were seen in the complete remission or event-free survival rates between patients with mutated or wild-type NOTCH1-FBXW7 (p=0.39).
  • CONCLUSIONS: NOTCH1 and FBXW7 mutations were not predictive of outcome in the overall cohort of adult patients with T-lymphoblastic leukemia, but there was a trend towards a favorable prognostic impact of NOTCH1-FBXW7 mutations in the small subgroup of patients with low-risk ERG/BAALC expression status.
  • Our findings further confirm the high frequency of NOTCH1 mutations in adult T-lymphoblastic leukemia.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate / trends. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Sep 21;276(38):35847-53 [11461910.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1589-95 [12886247.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Semin Cell Dev Biol. 2005 Jun;16(3):323-33 [15840441.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1841-3 [16079893.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4714-20 [16954520.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:169-77 [17124057.001]
  • [Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1879-82 [17332312.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] J Exp Med. 2007 Nov 26;204(12):2875-88 [17984302.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6964-9 [18056171.001]
  • [Cites] Leukemia. 2008 Jan;22(1):124-31 [17928886.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1154-60 [18368072.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] Nat Med. 2009 Jan;15(1):50-8 [19098907.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [CommentIn] Haematologica. 2009 Oct;94(10):1338-40 [19794079.001]
  • (PMID = 19794083.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Receptor, Notch1; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC2754954
  •  go-up   go-down


9. Dhédin N, Dombret H, Thomas X, Lhéritier V, Boiron JM, Rigal-Huguet F, Vey N, Kuentz M, Reman O, Witz F, Delannoy A, Kovacsovics T, Bradstock K, Charrin C, Boucheix C, Gabert J, Blaise D, Fière D, Vernant JP: Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia; 2006 Feb;20(2):336-44
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials.
  • To evaluate the results of autologous stem cell transplantation (ASCT) in a large population of adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR), we performed an individual data-based overview of the last three trials from the LALA group.
  • [MeSH-major] Peripheral Blood Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Recurrence. Remission Induction. Risk Factors. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357838.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


10. Maggio R, Peragine N, Calabrese E, De Propris MS, Intoppa S, Della Starza I, Ariola C, Vitale A, Foà R, Guarini A: Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission. Leuk Lymphoma; 2007 Feb;48(2):302-10
MedlinePlus Health Information. consumer health - Immunization.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission.
  • The capacity to generate effective dendritic cells (DC) from adult acute lymphoblastic leukemia (ALL) patients in complete remission (CR) and off-therapy was investigated.
  • DC loaded with leukemia-derived apoptotic bodies increased their ability to stimulate both allogeneic and autologous lymphocytes, and to generate specific anti-leukemic CD3 + cells.
  • These findings offer a rationale for the design of DC-based vaccine programs for adult ALL patients in CR with the aim of controlling/eradicating the disease.
  • [MeSH-major] Apoptosis. Dendritic Cells / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control. Vaccination
  • [MeSH-minor] Adult. Aged. Cancer Vaccines / therapeutic use. Cell Proliferation. Female. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Immunophenotyping. Interferon-gamma / metabolism. Interleukin-12 / metabolism. Interleukin-4 / pharmacology. Killer Cells, Natural / immunology. Male. Middle Aged. Phagocytosis. Remission Induction. T-Lymphocytes / immunology. T-Lymphocytes / metabolism. T-Lymphocytes / pathology. T-Lymphocytes, Cytotoxic / immunology. Tumor Cells, Cultured. Tumor Necrosis Factor-alpha / pharmacology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Feb;48(2):217-8 [17325876.001]
  • (PMID = 17325890.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Tumor Necrosis Factor-alpha; 187348-17-0 / Interleukin-12; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


11. Lonetti A, Iacobucci I, Ferrari A, Messina M, Cilloni D, Soverini S, Papayannidis C, Baccarani M, Foà R, Martinelli G: Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients. J Clin Oncol; 2009 May 20;27(15_suppl):7049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients.
  • : 7049 Since the activation-induced cytidine deaminase (AID) enzyme can target non-immunoglobulin (Ig) genes and may even act as a genome-wide mutator, we investigated AID expression in BCR-ABL1-positive ALL and in chronic myeloid leukemia (CML) at the time of progression to blast crisis.
  • On the 61 de novo adult BCR-ABL1-positive ALL patients (pts), AID mRNA and protein were detected in 36 (59%); their expression correlated with BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors at the time of remission.
  • AID expression was also found in lymphoid blast crisis CML (50%), but not in myeloid lineage or in chronic phase CML.
  • Our findings show that BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that can act as mutator outside the Ig gene loci in promoting genetic instability in leukemia cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961429.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Hafeez M, Shaharyar A, Zia N, Rasheed H: A phase II feasibility study of cytarabine and idarubicin combination in relapsed or refractory adult acute lymphoblastic leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e18002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II feasibility study of cytarabine and idarubicin combination in relapsed or refractory adult acute lymphoblastic leukemia.
  • : e18002 Background: Most patients with adult ALL eventually relapse.
  • Exact merit of each combination remains undefined as these continue to be tested in non randomized trials.
  • It was empirically decided that the study will only be considered feasible if more then ten patients achieve a complete remission.
  • Eleven patients achieved complete remission.
  • CONCLUSIONS: The regimen of cytrarabine and idarubicin is feasible and sufficiently effective in relapsed or refractory adult ALL with manageable toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964000.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Usvasalo A, Räty R, Knuutila S, Vettenranta K, Harila-Saari A, Jantunen E, Kauppila M, Koistinen P, Parto K, Riikonen P, Salmi TT, Silvennoinen R, Elonen E, Saarinen-Pihkala UM: Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica; 2008 Aug;93(8):1161-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia in adolescents and young adults in Finland.
  • BACKGROUND: Interest has recently been paid to adolescents and young adults with acute lymphoblastic leukemia, particularly because all reports so far published indicate that these patients have a better outcome when treated with pediatric rather than adult therapeutic protocols.
  • There are different biological subtypes of acute lymphoblastic leukemia with distinct features and prognoses; the distribution of these subtypes is not well known among adolescents.
  • We, therefore, studied acute lymphoblastic leukemia in adolescents and young adults aged 10 to 25 years in Finland.
  • DESIGN AND METHODS: This population-based study included 225 consecutive patients aged 10-25 years diagnosed with acute lymphoblastic leukemia during 1990-2004.
  • One hundred and twenty-eight patients (10-16 years) were treated with pediatric Nordic (NOPHO) protocols, and 97 patients (17-25 years) with Finnish Leukemia Group National protocols.
  • RESULTS: For the whole cohort, the remission rate was 96%, 5-year event-free survival 62% and overall survival 72%.
  • The 5-year event-free survival was 67% for the pediatric treatment group and 60% for the adult treatment group (p=n.s.).
  • CONCLUSIONS: Unlike all previous studies, we found that the outcome of adolescents and young adults with acute lymphoblastic leukemia treated with pediatric or adult therapeutic protocols was comparable.
  • The success of the adult acute lymphoblastic leukemia therapy emphasizes the benefit of central referral of patients to academic centers and adherence to research protocols.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Blast Crisis. Child. Disease-Free Survival. Female. Finland. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / mortality. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukocyte Count. Male. Phenotype. Philadelphia Chromosome. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Aug;93(8):1124-8 [18669975.001]
  • (PMID = 18556413.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Jarfelt M, Kujacic V, Holmgren D, Bjarnason R, Lannering B: Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Nov;49(6):835-40
MedlinePlus Health Information. consumer health - Heart Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia.
  • OBJECTIVE: Anthracyclines (AC) have contributed significantly to increased survival rate in acute lymphoblastic leukemia (ALL), although the use of these drugs is limited due to cardiotoxicity.
  • The aim was to evaluate heart muscle function in asymptomatic adult survivors of ALL treated in early childhood in relation to the combined effects of AC and other potential cardiotoxic factors.
  • PROCEDURE: Twenty-three young adult ALL survivors who had all received treatment with median 120 (120-400) mg AC/m(2) before the onset of puberty were examined median 21 years after remission and compared with 12 healthy controls.
  • [MeSH-major] Echocardiography, Stress. Exercise Test. Heart Diseases / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Anthracyclines / adverse effects. Anthracyclines / therapeutic use. Echocardiography, Doppler. Female. Follow-Up Studies. Human Growth Hormone / deficiency. Humans. Male. Risk Factors. Survivors


15. Burmeister T, Gökbuget N, Schwartz S, Fischer L, Hubert D, Sindram A, Hoelzer D, Thiel E: Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia. Haematologica; 2010 Feb;95(2):241-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia.
  • BACKGROUND: The t(9;22) and t(4;11) chromosomal translocations, which generate the BCR-ABL and MLL-AF4 fusion genes, define high-risk subtypes of acute lymphoblastic leukemia in adults.
  • However, the prognostic impact of other rarer fusion genes is less well established in adult acute lymphoblastic leukemia than in the childhood form.
  • DESIGN AND METHODS: In the context of the German Multicenter Therapy Study Group for Adult Acute Lymphoblastic Leukemia (GMALL) we used reverse transcriptase polymerase chain reaction to investigate 441 cases of BCR-ABL- and MLL-AF4-negative B-precursor acute lymphoblastic leukemia for the TCF3-PBX1 (E2A-PBX1) and ETV6-RUNX1 (TEL-AML1) fusion transcripts generated by the t(1;19)(q23;p13.3) and t(12;21)(p13;q22) translocations.
  • Both are well-known molecular alterations in pediatric acute lymphoblastic leukemia in which they have favorable prognostic implications.
  • RESULTS: We identified 23 adult patients with TCF3-PBX1 and ten with ETV6-RUNX1.
  • At 2 years after diagnosis all the ETV6-RUNX1-positive patients were alive and in continuous complete remission, but their long-term outcome was negatively affected by late relapses.
  • CONCLUSIONS: In contrast to previous suggestions, adult patients with TCF3-PBX1-positive acute lymphoblastic leukemia do not appear to have a worse outcome than their negative counterparts.
  • [MeSH-major] Oncogene Proteins, Fusion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Cell Line. Core Binding Factor Alpha 2 Subunit. Female. Fusion Proteins, bcr-abl. Humans. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Dec;13(12):1901-28 [10602411.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1406-9 [19282835.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2517-22 [11289124.001]
  • [Cites] Haematologica. 2001 Apr;86(4):438-9 [11325655.001]
  • [Cites] Leukemia. 2001 Aug;15(8):1293-300 [11480574.001]
  • [Cites] Leuk Lymphoma. 2001 Jun;42(1-2):41-56 [11699220.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1536-43 [11861265.001]
  • [Cites] Leukemia. 2002 Apr;16(4):669-74 [11960348.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1233-58 [12094248.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):484-7 [12580965.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1589-95 [12886247.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:102-31 [14633779.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4238-48 [15156179.001]
  • [Cites] Cancer Sci. 2004 Jun;95(6):503-7 [15182431.001]
  • [Cites] Eur J Cancer. 1977 Apr-May;13(4-5):377-9 [194778.001]
  • [Cites] Blood. 1984 Mar;63(3):721-4 [6607758.001]
  • [Cites] Blood. 1990 Jul 1;76(1):117-22 [2364165.001]
  • [Cites] Blood. 1991 Feb 15;77(4):687-93 [1671560.001]
  • [Cites] Leukemia. 1992 May;6(5):363-9 [1593901.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Mar;9(3):186-91 [7515661.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2601-6 [7989935.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 23;92(11):4917-21 [7761424.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3662-70 [7780150.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Leukemia. 1996 Sep;10(9):1456-8 [8751462.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4252-8 [8943861.001]
  • [Cites] Br J Haematol. 1996 Dec;95(4):673-7 [8982044.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1143-6 [9028935.001]
  • [Cites] Curr Top Microbiol Immunol. 1997;220:25-43 [9103673.001]
  • [Cites] Blood. 1997 Jul 15;90(2):571-7 [9226156.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):93-100 [9359508.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1898-909 [9731046.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Feb;109(1):58-65 [9973961.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):162-74 [15826831.001]
  • [Cites] Leukemia. 2005 May;19(5):806-13 [15744350.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2155-61 [17039234.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2178-81 [17039237.001]
  • [Cites] Leukemia. 2007 Apr;21(4):622-6 [17301806.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1561-4 [18024406.001]
  • [Cites] Haematologica. 2007 Dec;92(12):1699-702 [18055996.001]
  • [Cites] Blood Cells Mol Dis. 2008 Mar-Apr;40(2):211-8 [17920312.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jan 15;124(2):132-6 [11172904.001]
  • (PMID = 19713226.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / TCF3-PBX1 fusion protein, human; 0 / TEL-AML1 fusion protein; 0 / abl-bcr fusion protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Other-IDs] NLM/ PMC2817026
  •  go-up   go-down


16. Litzow MR: Evolving paradigms in the therapy of Philadelphia-chromosome-negative acute lymphoblastic leukemia in adults. Hematology Am Soc Hematol Educ Program; 2009;:362-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving paradigms in the therapy of Philadelphia-chromosome-negative acute lymphoblastic leukemia in adults.
  • Important studies challenging previous approaches to the treatment of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) have emerged in the past decade.
  • Donor versus no donor comparisons of allogeneic transplant highlight a potent graft-versus-leukemia effect in ALL, and the application of reduced-intensity conditioning transplants may exploit this effect while reducing non-relapse mortality.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008222.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 70
  •  go-up   go-down


17. Wu WL, Liang JY, Zhu MQ, Xue YQ, Chen ZX: [MIC categorization of acute lymphoblastic leukemia with myeloid surface antigen expression]. Zhonghua Xue Ye Xue Za Zhi; 2007 Nov;28(11):754-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MIC categorization of acute lymphoblastic leukemia with myeloid surface antigen expression].
  • OBJECTIVE: To explore the characteristics of morphology, immunophenotype and cytogenetics (MIC) of myeloid surface antigen-expressing acute lymphoblastic leukemia (My+ ALL).
  • METHODS: One hundred and twenty untreated acute lymphoblastic leukemia (ALL) patients were diagnosed by standard bone marrow smear morphologic analysis and peroxidase staining.
  • Flow cytometry and myeloid monoclonal antibodies (McAb) were used to analyze immunophenotype.
  • Of 66 My+ ALL, 10 cases (15.1%) were misdiagnosed as acute non-lymphoblastic leukemia (ANLL), the other 54 My- ALL cases were correctly diagnosed.
  • The complete remission (CR) rates was 83.9% in My+ ALL and 79% in My- ALL(P > 0.05).
  • Some cases have a myeloid morphologic appearance and might be misdiagnosed as acute myeloid leukemia (AML).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunophenotyping. Karyotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457267.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, Liakopoulou E, Fielding AK, Mackinnon S, Olavarria E, Potter MN, Russell NH, Shaw BE, Cook G, Goldstone AH, Marks DI: Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica; 2009 Oct;94(10):1399-406
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission.
  • BACKGROUND: Approximately 40% of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia achieve long-term survival following unrelated donor hematopoietic stem cell transplantation in first complete remission but severe graft-versus-host disease remains a problem affecting survival.
  • Although T-cell depletion abrogates graft-versus-host disease, the impact on disease-free survival in acute lymphoblastic leukemia is not known.
  • DESIGN AND METHODS: We analyzed the outcome of 48 adults (median age 26 years) with high-risk, Philadelphia-chromosome-negative acute lymphoblastic leukemia undergoing T-cell depleted unrelated donor-hematopoietic stem cell transplantation (67% 10 of 10 loci matched) in first complete remission reported to the British Society of Blood and Marrow Transplantation Registry from 1993 to 2005.
  • Overall survival, disease-free survival and non-relapse mortality rates at 5 years were 61% (95% CI 46-75), 59% (95% CI 45-74) and 13% (95% CI 3-25), respectively.
  • The incidences of grades II-IV and III-IV acute graft-versus-host disease were 27% (95% CI 16-44) and 10% (95% CI 4-25), respectively.
  • CONCLUSIONS: T-cell depleted hematopoietic stem cell transplantation from unrelated donors can result in good overall survival and low non-relapse mortality for adults with high-risk acute lymphoblastic leukemia in first complete remission and merits prospective evaluation.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Humanized. Female. Follow-Up Studies. Humans. Living Donors. Male. Middle Aged. Registries. Remission Induction. Risk Factors. Survival Rate / trends. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2000 Feb;25(4):411-7 [10723585.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Nov;14(11):1245-52 [18940679.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(1):69-76 [10918407.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] Cytotherapy. 2001;3(3):197-201 [12171726.001]
  • [Cites] Blood. 2003 Jul 1;102(1):404-6 [12623851.001]
  • [Cites] Ann Hematol. 2004 Apr;83(4):201-5 [14648023.001]
  • [Cites] Blood. 2004 May 15;103(10):3986-8 [14764530.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Haematologica. 2004 Jul;89(7):809-17 [15257932.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Lancet. 1987 Jul 25;2(8552):175-8 [2885638.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Blood. 1991 Oct 15;78(8):2120-30 [1912589.001]
  • [Cites] N Engl J Med. 1993 Mar 4;328(9):593-602 [8429851.001]
  • [Cites] Transplantation. 1994 Oct 27;58(8):887-91 [7940731.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2580-7 [7989932.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):305-8 [8704678.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):931-6 [9508175.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3028-37 [15256423.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3308-13 [16046530.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):155-63 [16284608.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2657-63 [16703597.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Blood. 2008 Jul 15;112(2):426-34 [18398065.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3996-4003 [10845940.001]
  • (PMID = 19648167.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  • [Other-IDs] NLM/ PMC2754956
  •  go-up   go-down


19. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G: Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood; 2009 Feb 26;113(9):1892-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
  • Pretreatment aberrant DNA methylation patterns are stable at time of relapse in acute lymphocytic leukemia (ALL).
  • We hypothesized that the detection of residual methylation alterations at the time of morphologic remission may predict for worse prognosis.
  • We developed a real-time bisulfite polymerase chain reaction assay and analyzed the methylation levels of p73, p15, and p57(KIP2) at the time of initial remission in 199 patients with Philadelphia chromosome-negative and MLL(-) ALL.
  • In 123 (65%) patients, matched pretreatment samples were also studied and compared with remission ones: in 82 of those with initial aberrant methylation of at least one gene, 59 (72%) had no detectable methylation at remission and 23 (28%) had detectable residual methylation.
  • By multivariate analysis, the presence of residual p73 methylation was associated with a significant shorter duration of first complete remission (hazard ratio=2.68, P= .003) and overall survival (hazard ratio=2.69, P= .002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D25-30 [18073190.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):163-205 [11253606.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):11-9 [11262868.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1897-903 [12060634.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2217-24 [12114423.001]
  • [Cites] Blood. 2003 May 15;101(10):4131-6 [12586619.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1845-50 [12970785.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2492-8 [15198948.001]
  • [Cites] Hematol Oncol Clin North Am. 1993 Feb;7(1):139-60 [8449856.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3932-9 [15851765.001]
  • [Cites] Leuk Res. 2005 Aug;29(8):881-5 [15978938.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1370-7 [17283175.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1381-96, x-xi [11147229.001]
  • (PMID = 19109226.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA105771; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA100067; United States / NCI NIH HHS / CA / R21 CA100067; United States / NCI NIH HHS / CA / CA105771
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  • [Other-IDs] NLM/ PMC2651008
  •  go-up   go-down


20. Marks DI, Forman SJ, Blume KG, Pérez WS, Weisdorf DJ, Keating A, Gale RP, Cairo MS, Copelan EA, Horan JT, Lazarus HM, Litzow MR, McCarthy PL, Schultz KR, Smith DD, Trigg ME, Zhang MJ, Horowitz MM: A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant; 2006 Apr;12(4):438-53
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.
  • We compared the outcomes of 298 patients with acute lymphoblastic leukemia in first or second complete remission (CR1 or CR2) receiving HLA-matched sibling allografts after cyclophosphamide and total body irradiation (Cy-TBI) conditioning with 204 patients receiving etoposide and TBI.
  • Analyses of relapse, leukemia-free survival (LFS), and survival were performed separately for CR1 and CR2 transplantations.
  • We conclude that for HLA-identical sibling allografts for acute lymphoblastic leukemia in CR2, there is an advantage in substituting etoposide for Cy or, when Cy is used, in increasing the TBI dose to > or =13 Gy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Hematopoietic Stem Cell Transplantation. Myeloablative Agonists / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Prospective Studies. Remission Induction. Siblings. Survival Rate. Transplantation, Homologous. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545728.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Myeloablative Agonists; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


21. Lee S, Chung NG, Cho BS, Eom KS, Kim YJ, Kim HJ, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Kim CC: Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia. Leukemia; 2010 Dec;24(12):2110-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia.
  • We analyzed long-term outcomes of myeloablative stem cell transplantation (SCT) in 292 adults with Philadelphia (Ph)-negative acute lymphoblastic leukemia (ALL).
  • MM-URD-SCT yielded higher risk of non-relapse mortality than RD-SCT (P=0.010).
  • Other factors associated with poorer DFS included SCT beyond first complete remission (CR), older age and adverse cytogenetics.
  • SCT using RD, WM-URD or PM-URD may be considered the best donor sources for adult high-risk Ph-negative ALL.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tissue Donors
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Graft vs Host Disease / etiology. Humans. Male. Middle Aged. Risk Factors. Treatment Outcome


22. Amirghofran Z, Daneshbod Y, Gholijani N: Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome. Oncol Res; 2009;17(10):447-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome.
  • The present study was performed to find the importance of two myeloid (CD13 and CD33) antigens aberrantly expressed on the blasts of acute lymphoblastic leukemia (ALL) patients and Bcl-2 expression in relation to clinical and biological features and treatment outcome.
  • Aberrant expression of myeloid antigens was found in 14% of cases.
  • A significant correlation between expression of myeloid antigens (MY) and survival and complete remission duration was found.
  • Expression of Bcl-2 in combination to myeloid antigens was associated with a poorer outcome.
  • In conclusion, results of this study indicated the prognostic value of Bcl-2 and myeloid antigen expression in ALL patients.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, CD13 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Bone Marrow / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Sialic Acid Binding Ig-like Lectin 3. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19725224.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


23. Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AM, Periclou AP, Avramis VI: Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood; 2007 Apr 1;109(7):2744-50
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.
  • We administered a single intravenous dose of pegaspargase (2000 IU/m2) as part of a standard frontline induction regimen to 25 adults with newly diagnosed acute lymphoblastic leukemia (ALL), and obtained serum samples on several time points.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Asparaginase / pharmacology. Polyethylene Glycols / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Clinical Protocols. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Remission Induction / methods. Safety. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17132721.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / pegaspargase; 30IQX730WE / Polyethylene Glycols; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


24. Jarfelt M, Lannering B, Bosaeus I, Johannsson G, Bjarnason R: Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol; 2005 Jul;153(1):81-9
MedlinePlus Health Information. consumer health - Obesity in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body composition in young adult survivors of childhood acute lymphoblastic leukaemia.
  • Obesity, particularly abdominal obesity, is one of the main characteristics of the metabolic syndrome and a risk factor for cardiovascular disease and non-insulin-dependent diabetes mellitus (NIDDM).
  • DESIGN: All patients treated for acute lymphoblastic leukaemia (ALL) before the onset of puberty in the region of western Sweden, between 1973 and 1985, and in first remission, were included.
  • CONCLUSIONS: We found little effect on BMI but an increased percentage of total body fat, especially trunk fat, and a tendency for an unfavourable lipid profile in adult survivors of childhood leukaemia.

  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994749.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leptin; 0 / Lipids
  •  go-up   go-down


25. Battisti V, Maders LD, Bagatini MD, Santos KF, Spanevello RM, Maldonado PA, Brulé AO, Araújo Mdo C, Schetinger MR, Morsch VM: Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia patients. Clin Biochem; 2008 May;41(7-8):511-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia patients.
  • OBJECTIVES: To evaluate the oxidative status and antioxidant defense in patients with acute lymphoblastic leukemia (ALL).
  • This study was performed on 80 children with ALL divided into 4 groups: just diagnosed, remission induction, remission maintenance and out-of-treatment.
  • CONCLUSION: These findings may indicate a possible link between decreased antioxidants and increased levels of cells alterations due to oxidative damage, supporting the idea that there is a persistence of oxidative stress in acute lymphoblastic leukemia.
  • [MeSH-major] Antioxidants / metabolism. Oxidative Stress / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Lipid Peroxidation / physiology. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313403.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants
  •  go-up   go-down


26. Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, Ciuffreda L, Pietrantuono G, Liso V: FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol; 2005 Nov;84(12):792-5
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
  • Relapsed or refractory adult acute lymphoblastic leukemias (ALL) have poor prognosis.
  • Twenty three patients with relapsed/refractory adult ALL were treated with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA).
  • Nine (39.1%) patients achieved complete remission (CR) following salvage therapy, whereas 13 (56.5%) patients were refractory, and one patient died in aplasia due to infection.
  • In patients achieving remission, the median time to reach absolute neutrophil count (ANC) more than 0.5x10(9)/l and 1x10(9)/l was 20 (range 16-25) and 24 (range 20-28) days from the start of chemotherapy, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / adverse effects. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Leukocyte Count. Liver / injuries. Male. Middle Aged. Mucositis / etiology. Platelet Count. Recurrence. Remission Induction. Retrospective Studies. Salvage Therapy. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16047203.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


27. Campana D: Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program; 2010;2010:7-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease in acute lymphoblastic leukemia.
  • In patients with acute lymphoblastic leukemia (ALL), treatment response is increasingly evaluated with minimal residual disease (MRD) assays.
  • ALL cells can be recognized by their clonal rearrangement of immunoglobulin and T-cell receptor genes, expression of gene fusions, and leukemia-associated immunophenotypes.
  • The vast majority of cases have antigen-receptor gene rearrangements and leukemia immunophenotypes for MRD monitoring; about half of the cases currently have suitable gene fusions.
  • The clinical significance of MRD has been conclusively demonstrated in both childhood and adult ALL.
  • In most studies, MRD positivity is defined by the presence of 0.01% or more ALL cells; the risk of relapse is generally proportional to the level of MRD, particularly when measured during or at the end of remission-induction therapy.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21239764.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA60419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP, George B, Gupta V, Halter J, Khoury HJ, Klumpp TR, Lazarus HM, Lewis VA, McCarthy P, Rizzieri DA, Sabloff M, Szer J, Tallman MS, Weisdorf DJ: The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood; 2010 Jul 22;116(3):366-74
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.
  • We examined the efficacy of reduced-intensity conditioning (RIC) and compared outcomes of 93 patients older than 16 years after RIC with 1428 patients receiving full-intensity conditioning for allografts using sibling and unrelated donors for Philadelphia-negative acute lymphoblastic leukemia (ALL) in first or second complete remission.
  • The RIC versus full-intensity conditioning groups had slightly, but not significantly, less acute grade II-IV graft-versus-host disease (39% vs 46%) and chronic graft-versus-host disease (34% vs 42%), yet similar transplantation-related mortality.
  • Multivariate analysis demonstrated significantly improved overall survival with: Karnofsky performance status more than 80, first complete remission, lower white blood count, well-matched unrelated or sibling donors, transplantation since 2001, age younger than 30 years, and conditioning with TBI, but no independent impact of conditioning intensity.
  • RIC merits further investigation in prospective trials of adult ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Oct 1;96(7):2419-25 [11001893.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33 [19896087.001]
  • [Cites] N Engl J Med. 1979 May 10;300(19):1068-73 [34792.001]
  • [Cites] Blood. 1989 May 1;73(6):1720-8 [2653460.001]
  • [Cites] Bone Marrow Transplant. 1998 Jan;21(2):153-8 [9489632.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Bone Marrow Transplant. 2005 Mar;35(6):549-56 [15756282.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):683-9 [16113673.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Bone Marrow Transplant. 2006 Oct;38(7):467-75 [16892073.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Haematologica. 2008 Feb;93(2):303-6 [18245655.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Bone Marrow Transplant. 2008 Apr;41(7):635-42 [18084335.001]
  • [Cites] Blood. 2008 Jul 15;112(2):426-34 [18398065.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Mar;15(3):367-9 [19203728.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2902-5 [19179301.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3634-41 [19581540.001]
  • [Cites] Haematologica. 2009 Oct;94(10):1399-406 [19648167.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Nov;15(11):1407-14 [19822300.001]
  • [Cites] Haematologica. 2003 May;88(5):555-60 [12745275.001]
  • (PMID = 20404137.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / U24 CA076518; United States / PHS HHS / / HHSH234200637015C; United States / NCI NIH HHS / CA / U24-CA76518; United States / NHLBI NIH HHS / HL / U01 HL069294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] G1LN9045DK / Busulfan; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC2913452
  •  go-up   go-down


29. Xu B, Song X, Yip NC, Xiao P, Zhang Y, Wang W, Zhou S: Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. Hematology; 2010 Apr;15(2):74-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia.
  • The interaction between Wilms tumor gene 1 (WT1) and the promoter region of the multidrug resistance-1 (MDR1) gene has been previously reported but the clinical significance of the coexpression of WT1 and MDR1 in acute lymphoblastic leukemia (ALL) is still largely unknown.
  • In this study, the expression levels of WT1 and MDR1 mRNA in 57 adult ALL patients were simultaneously detected using multiplex fluorescence real-time quantitative polymerase chain reaction.
  • The expression levels of WT1 and MDR1 in bone marrow samples of adult ALL patients were significantly higher than those in the normal samples (P<0.001), and in addition, the expression levels of WT1 and MDR1 mRNA were highly correlated (r(s)=0.404, P=0.002).
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Marrow / chemistry. Gene Expression Regulation, Leukemic. Genes, Wilms Tumor. Neoplasm Proteins / analysis. P-Glycoprotein / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. WT1 Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm / genetics. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. P-Glycoproteins. Prognosis. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423567.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / WT1 Proteins; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; CVAD protocol
  •  go-up   go-down


30. Plensa E, Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández Ribas JM, Moreno MJ, del Potro E, Tormo M, Rivas C, Besalduch J, Sanz MA, Arias J, Fernández Calvo J, Moraleda JM, Bueno J, Feliu E, Ortega JJ, Grupo PETHEMA: [Prevalence and prognostic significance of myeloid markers in adults with high-risk acute lymphoblastic leukemia]. Med Clin (Barc); 2005 Sep 3;125(7):241-6
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prevalence and prognostic significance of myeloid markers in adults with high-risk acute lymphoblastic leukemia].
  • BACKGROUND AND OBJECTIVE: The prognostic value of myeloid antigen expression in adult acute lymphoblastic leukemia (ALL) is controversial.
  • The objective of this study was to evaluate the frequency and prognostic significance of myeloid antigen expression in adults with high risk ALL.
  • The frequency of myeloid antigen expression, its association with other clinical and biologic variables and the prognostic significance in terms of complete remission (CR) rate, event free survival (EFS) and overall survival (OS) were analyzed.
  • RESULTS: Myeloid antigen expression was present in 96 out of 222 patients (43%).
  • No association was observed between myeloid antigen expression and the main clinical and biologic characteristics of ALL.
  • Response to treatment was slower in patients expressing myeloid antigens, but no differences were found in CR achievement, EFS or OS.
  • The probability of EFS at 10 years for ALL patients without and with myeloid antigen expression was 35% and 34%, respectively, while the probability of OS at 10 years was 30% and 33%, respectively.
  • CONCLUSIONS: In this study, myeloid antigen expression did not have prognostic influence in adult patients with high risk ALL.
  • [MeSH-major] Antigens, CD / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Immunophenotyping. Male. Prevalence. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137483.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


31. Vitale A, Guarini A, Ariola C, Meloni G, Perbellini O, Pizzuti M, De Gregoris C, Mettivier V, Pastorini A, Pizzolo G, Vignetti M, Mandelli F, Foà R: Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Haematologica; 2007 Mar;92(3):342-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial.
  • BACKGROUND AND OBJECTIVES: The prognostic value of myeloid antigen (MyAg) expression in adult acute lymphoblastic leukemia (ALL) is still controversial.
  • The aim of this study was to correlate the expression of MyAg with clinical, hematologic and biological parameters, and to analyze the impact on response to treatment and prognosis in a large series of adult ALL uniformly characterized and treated.
  • DESIGN AND METHODS: We analyzed the expression of the MyAg CD13 and/or CD33 in a cohort of 377 adult patients with de novo ALL enrolled and treated in the GIMEMA ALL 0496 protocol.
  • RESULTS: MyAg expression was documented in 35% of the 377 adult ALL cases analyzed.
  • We failed to observe any difference between MyAg-positive and MyAg-negative cases in terms of achievement of complete remission, disease-free survival and overall survival at 5 years.
  • INTERPRETATION AND CONCLUSIONS: Our data indicate that ALL MyAg expression in adults with ALL is not associated with adverse presenting clinical and biological features, and that response to treatment and prognosis is comparable in MyAg-positive and MyAg-negative ALL patients with regards to both complete remission rate and overall survival.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD13 / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Antigens, Neoplasm / biosynthesis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Randomized Controlled Trials as Topic / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blood Cell Count. Burkitt Lymphoma / blood. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / mortality. Burkitt Lymphoma / radiotherapy. Cell Lineage. Cohort Studies. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Humans. Immunophenotyping. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / mortality. Leukemia-Lymphoma, Adult T-Cell / radiotherapy. Male. Middle Aged. Multicenter Studies as Topic / statistics & numerical data. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339183.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antigens, Neoplasm; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 04079A1RDZ / Cytarabine; EC 3.4.11.2 / Antigens, CD13; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


32. Ottmann OG, Wassmann B: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program; 2005;:118-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • Philadelphia chromosome positive (Ph(+)) acute lymphoblastic leukemia (ALL) includes at least one-quarter of all adults with ALL.
  • Allogeneic stem cell transplantation early in first remission has been the recommended therapy.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304368.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; VB0R961HZT / Prednisone
  •  go-up   go-down


33. Ferrá C, Sanz J, de la Cámara R, Sanz G, Bermúdez A, Valcárcel D, Rovira M, Serrano D, Caballero D, Espigado I, Morgades M, Heras I, Solano C, Duarte R, Barrenetxea C, García-Noblejas A, Díez-Martin JL, Iriondo A, Carreras E, Sierra J, Sanz MA, Ribera JM, GETH (Grupo Español de Trasplante Hematopoyético) and PETHEMA (Programa Español de Tratamiento en Hematología), Spanish Society of Hematology: Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source. Biol Blood Marrow Transplant; 2010 Jul;16(7):957-66
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
  • Adults with high-risk acute lymphoblastic leukemia (HR-ALL) have a poor outcome with standard chemotherapy and usually undergo unrelated stem cell transplantation (SCT) if a matched sibling donor is not available.
  • We analyzed the outcome of adult patients with unrelated SCT for HR-ALL and studied the possible effect of the hematopoietic stem cell source of the transplant.
  • A total of 149 adult patients (median age, 29 years, range, 15-59 years) with HR-ALL underwent unrelated SCT in 13 Spanish institutions between 2000 and 2007.
  • Patients in first complete remission (CR1) at transplantation had at least one adverse prognostic factor (advanced age, adverse cytogenetics, hyperleukocytosis, or slow response to induction therapy).
  • All unrelated transplantation modalities were associated with high treatment-related mortality for adult HR-ALL patients without a sibling donor.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Humans. Living Donors. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Survivors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20144909.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Hoelzer D, Gökbuget N: T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma; 2009;9 Suppl 3:S214-21
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?
  • T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are considered the same disease, differing by the extent of bone marrow infiltration.
  • Treatment approaches in T-LBL changed from conventional non-Hodgkin lymphoma (NHL) protocols to intensive NHL protocols but recently to ALL-designed protocols.
  • T-ALL remission rates are 90%, and overall survival (OS) has improved to 60%-70%.
  • Autologous SCT in complete remission (CR) in T-LBL gives a 70% survival rate, which is similar to chemotherapy alone.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Leukemic. Humans. Immunophenotyping. Male. Mediastinum / pathology. Medical Oncology / methods. Middle Aged. Prognosis. Remission Induction. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778844.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


35. Huang L, Lequin M, Pieters R, van den Heuvel-Eibrink MM: The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma. Pediatr Blood Cancer; 2007 Apr;48(4):468-72
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma.
  • BACKGROUND: The aim of this study was to evaluate the value of follow-up investigations of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin's lymphoma (T-NHL), including cerebrospinal fluid (CSF) examination, bone marrow (BM) aspiration, peripheral blood (PB) count, serum lactate dehydrogenase (LDH) and chest X-rays in patients with an initial mediastinal enlargement.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / blood. Bone Marrow Examination. Child. Child, Preschool. Diagnostic Tests, Routine. Disease Management. Follow-Up Studies. Humans. Incidence. Infant. L-Lactate Dehydrogenase / blood. Leukemic Infiltration / diagnosis. Leukemic Infiltration / epidemiology. Mediastinum / pathology. Prognosis. Recurrence. Remission Induction. Retrospective Studies


36. Horstmann MA, Hassenpflug WA, zur Stadt U, Escherich G, Janka G, Kabisch H: Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children. Haematologica; 2005 Dec;90(12):1701-3
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
  • In a retrospective analysis of 24 children with refractory or multiply relapsed acute lymphoblastic leukemia (ALL), a salvage regimen comprising amsacrine, etoposide, and high-dose methylprednisolone AEP achieved a significant treatment response in 11 of 19 evaluable patients (8 complete and 3 partial remissions).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Amsacrine / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Cytarabine / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dexamethasone / administration & dosage. Drug Evaluation. Drug Synergism. Etoposide / administration & dosage. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Idarubicin / administration & dosage. Infant. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / surgery. Male. Methylprednisolone / administration & dosage. Neoplasm, Residual. Peripheral Blood Stem Cell Transplantation. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / surgery. Prognosis. Recombinant Proteins. Remission Induction. Retrospective Studies. Survival Analysis. Thiotepa / administration & dosage. Topotecan / administration & dosage. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. AMSACRINE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330449.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Recombinant Proteins; 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7M7YKX2N15 / Topotecan; 7S5I7G3JQL / Dexamethasone; 905Z5W3GKH / Thiotepa; FA2DM6879K / Vidarabine; PVI5M0M1GW / Filgrastim; X4W7ZR7023 / Methylprednisolone; ZRP63D75JW / Idarubicin; AEP protocol; Ida-FLAG protocol; TVTG protocol
  •  go-up   go-down


37. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer; 2006 Apr 1;106(7):1569-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
  • BACKGROUND: Adult Burkitt-type lymphoma (BL) and acute lymphoblastic leukemia (B-ALL) are rare entities composing 1% to 5% of non-Hodgkin lymphomas NHL) or ALL.
  • RESULTS: Complete remission (complete response [CR]) was achieved in 24 of 28 (86%) evaluable patients; 3 had a partial response, and 1 had resistant disease.
  • CONCLUSIONS: The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL, particularly in elderly patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


38. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol; 2006 Jan 20;24(3):460-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
  • PURPOSE: A novel therapeutic approach is urgently needed for BCR-ABL-positive acute lymphoblastic leukemia (ALL).
  • RESULTS: Remission induction therapy resulted in complete remission (CR) in 77 patients (96.2%), resistant disease in one patient, and early death in two patients, as well as polymerase chain reaction negativity of bone marrow in 71.3%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fusion Proteins, bcr-abl / metabolism. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Benzamides. Feasibility Studies. Female. Humans. Imatinib Mesylate. Japan. Male. Middle Aged. Protein-Tyrosine Kinases / antagonists & inhibitors. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344315.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


39. Steinherz PG, Shukla N, Kobos R, Steinherz L: Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatr Blood Cancer; 2010 May;54(5):687-93
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
  • BACKGROUND: We determined the maximum tolerated dose (MTD) of clofarabine when administered with topotecan, vinorelbine, thiotepa, and dexamethasone (TVTC) for children with relapsed or refractory acute leukemia, and observed the efficacy and toxicities of this therapy.
  • PROCEDURE: Twelve patients with acute lymphoblastic or myeloblastic leukemia were given a 14-day remission induction therapy.
  • Patients who achieved a remission proceeded to a stem cell transplant (HSCT).
  • One patient died on day 45 with marrow hypoplasia without evidence of leukemia.
  • The one dose limiting non-infectious toxicity observed was prolonged marrow hypoplasia.
  • CONCLUSION: TVTC has significant anti-leukemic activity in both acute lymphoblastic and myeloblastic leukemia.
  • This is the recommended dose for the phase II study in patients with refractory or relapsed leukemia, a population which has limited therapeutic options.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy
  • [MeSH-minor] Adenine Nucleotides / administration & dosage. Adenine Nucleotides / adverse effects. Adolescent. Adult. Arabinonucleosides / administration & dosage. Arabinonucleosides / adverse effects. Child. Child, Preschool. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Hematopoietic Stem Cell Transplantation. Humans. Infant. Male. Maximum Tolerated Dose. Recurrence. Remission Induction. Thiotepa / administration & dosage. Thiotepa / adverse effects. Topotecan / administration & dosage. Topotecan / adverse effects. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205253.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 5V9KLZ54CY / Vinblastine; 762RDY0Y2H / clofarabine; 7M7YKX2N15 / Topotecan; 905Z5W3GKH / Thiotepa; Q6C979R91Y / vinorelbine
  •  go-up   go-down


40. Benmiloud S, Steffens M, Beauloye V, de Wandeleer A, Devogelaer JP, Brichard B, Vermylen C, Maiter D: Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-Hodgkin lymphoma during childhood. Horm Res Paediatr; 2010;74(4):241-50
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-Hodgkin lymphoma during childhood.
  • METHODS: Bone mineral density (BMD) was evaluated at lumbar spine (LS), total hip and femoral neck in 89 patients (44 men) more than 5 years after remission of childhood acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL).
  • CONCLUSIONS: A low bone mass is frequently observed in adult survivors of childhood ALL and NHL, and is associated with male gender at the LS and with dexamethasone treatment, cranial irradiation and BMT/TBI at the hip.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Density / drug effects. Bone Density / radiation effects. Lymphoma, Non-Hodgkin / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


41. Tavernier E, Le QH, de Botton S, Dhédin N, Bulabois CE, Reman O, Vey N, Lhéritier V, Dombret H, Thomas X: Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials. Cancer; 2007 Dec 15;110(12):2747-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials.
  • BACKGROUND: Second malignant neoplasms are a serious complication after successful treatment of childhood acute lymphoblastic leukemia (ALL).
  • RESULTS: By February 2005 secondary or concomitant neoplasms were documented in 23 patients, including 9 acute myeloid leukemias (AML) or myelodysplasias (MDS), 4 non-Hodgkin lymphomas (NHL), 5 skin tumors, and 5 other solid tumors (1 lung cancer, 1 tongue carcinoma, 1 thymoma, 1 condrosarcoma, 1 histiocytosis).
  • There were 22 patients in first remission and 1 was in second remission.
  • However, the median OS in patients developing AML/MDS was 5.7 months.
  • CONCLUSIONS: The data document that adult ALL survivors are at an increased risk of later malignancy.
  • Considering the low survival rate of this large unselected adult ALL cohort (32% at 10 years) as compared with that observed in childhood ALL, the risk of second malignancy remains underestimated.
  • [MeSH-major] Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Clinical Trials as Topic. Female. Humans. Incidence. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis


42. Li YN, Zou DH, Gu M, Mi YC, Wang JX, Qiu LG: [The role of BCR/ABL isoforms in the presentations and outcome of Philadelphia-positive acute lymphoblastic leukemia in adult patients]. Zhonghua Nei Ke Za Zhi; 2009 Jun;48(6):481-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of BCR/ABL isoforms in the presentations and outcome of Philadelphia-positive acute lymphoblastic leukemia in adult patients].
  • OBJECTIVE: To investigate the difference of clinical characteristics and outcomes between different isoforms of BCR/ABL in adults with Philadelphia-positive acute lymphoblastic leukemia (ALL).
  • Referring to the outcomes, the complete remission (CR) rate of the two groups were 92.2% and 93.9%, respectively.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Philadelphia Chromosome. Prognosis. Protein Isoforms / genetics. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954044.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / abl-bcr fusion protein, human; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


43. Stock W: Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma; 2010 Feb;51(2):188-98
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • The clinical management of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been challenging primarily due to the aggressive nature of the disease and limited effective treatment options.
  • The outcome for patients who receive conventional chemotherapy alone is poor, with remission duration of around 12 months and disease-free survival (DFS) rates of not more than 10%.
  • Remission duration also is improved when combination chemotherapy and imatinib are administered intensively, even in the absence of allogeneic stem cell transplant.
  • [MeSH-major] Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use. Thiazoles / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides. Clinical Trials as Topic. Dasatinib. Drug Resistance, Neoplasm. Fusion Proteins, bcr-abl / antagonists & inhibitors. Fusion Proteins, bcr-abl / genetics. Fusion Proteins, bcr-abl / metabolism. Humans. Imatinib Mesylate. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001232.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl; RBZ1571X5H / Dasatinib
  • [Number-of-references] 101
  •  go-up   go-down


44. Torelli GF, Guarini A, Maggio R, Alfieri C, Vitale A, Foà R: Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission. Haematologica; 2005 Jun;90(6):785-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
  • The anti-leukemic activity of NK cells against acute myeloid leukemia (AML) blasts has been described, but very few data are available for acute lymphoid leukemia (ALL).
  • The present study was designed to investigate whether: (i) NK effectors could be expanded from adult and pediatric ALL patients in complete remission;.
  • (v) any differences in cytotoxic activity could be found between expanded effectors from adult and pediatric patients.
  • No differences in expansion and cytotoxic activity were found between pediatric and adult patients.
  • INTERPRETATION AND CONCLUSIONS: These findings document for the first time the possibility of expanding ex vivo cytotoxic effectors with autologous killing capacity from ALL patients in remission, and suggest a new potential immunotherapeutic strategy for the management of early disease recurrence or of residual disease.
  • [MeSH-major] Immunotherapy / methods. Killer Cells, Natural / cytology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Child. Coculture Techniques. Cytokines / metabolism. Flow Cytometry. Humans. Interleukin-15 / metabolism. Interleukin-2 / metabolism. Receptors, IgG / metabolism. Remission Induction. Signal Transduction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951291.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-15; 0 / Interleukin-2; 0 / Receptors, IgG
  •  go-up   go-down


45. Liu J, Wu DS, Zhang S, Yan CH, Zhou Y, Zhang YD, Qi ZH: [Relation between the expression of sIL-2R and the relapse in patients with acute lymphoblastic leukemia]. Beijing Da Xue Xue Bao; 2005 Jun 18;37(3):249-51
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relation between the expression of sIL-2R and the relapse in patients with acute lymphoblastic leukemia].
  • OBJECTIVE: To explore the relation of the serum level of sIL-2R in relapse patients with acute lymphoblastic leukemia (ALL).
  • METHODS: With ELISA, we determined the levels of sIL-2R of 48 patients with ALL after their first diagnoses, complete remission 1 and relapse.
  • The levels of sIL-2R of 30 patients from complete remission 1 to relapse were monitored.
  • The levels of sIL-2R were higher in the relapse group and first diagnosed group than in the complete remission 1 group.
  • However, the difference between the complete remission 1 and the control had no statistical significance.
  • When we determined the levels of sIL-2R dynamically, we found that after complete remission, the levels of sIL-2R decreased, however, before one month of hematological relapse, the levels of sIL-2R increased.
  • [MeSH-major] Neoplasm Recurrence, Local / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Receptors, Interleukin-2 / blood
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968312.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-2
  •  go-up   go-down


46. Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A: Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol; 2010 Aug 1;28(22):3644-52
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.
  • PURPOSE: Short imatinib pulses were added to chemotherapy to improve the long-term survival of adult patients with Philadelphia chromosome (Ph) -positive acute lymphoblastic leukemia (ALL), to optimize complete remission (CR) and stem-cell transplantation (SCT) rates.
  • CONCLUSION: This imatinib-based protocol improved long-term outcome of adult patients with Ph-positive ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Aged. Benzamides. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Imatinib Mesylate. Italy. Male. Middle Aged. Prognosis. Remission Induction. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20606084.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


47. Oriol A, Vives S, Hernández-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardó F, Bueno J, Grande C, del Potro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM, Programa Español de Tratamiento en Hematologia Group: Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica; 2010 Apr;95(4):589-96
Andalusian Health Repository. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.
  • BACKGROUND: About one half of adults with acute lymphoblastic leukemia are not cured of the disease and ultimately die.
  • The objective of this study was to explore the factors influencing the outcome of adult patients with relapsed acute lymphoblastic leukemia.
  • DESIGN AND METHODS: We analyzed the characteristics, the outcome and the prognostic factors for survival after first relapse in a series of 263 adult patients with acute lymphoblastic leukemia (excluding those with mature B-cell acute lymphoblastic leukemia) prospectively enrolled in four consecutive risk-adapted PETHEMA trials.
  • RESULTS: The median overall survival after relapse was 4.5 months (95% CI, 4-5 months) with a 5-year overall survival of 10% (95% CI, 8%-12%); 45% of patients receiving intensive second-line treatment achieved a second complete remission and 22% (95% CI, 14%-30%) of them remained disease free at 5 years.
  • Factors predicting a good outcome after rescue therapy were age less than 30 years (2-year overall survival of 21% versus 10% for those over 30 years old; P<0.022) and a first remission lasting more than 2 years (2-year overall survival of 36% versus 17% among those with a shorter first remission; P<0.001).
  • Patients under 30 years old whose first complete remission lasted longer than 2 years had a 5-year overall survival of 38% (95% CI, 23%-53%) and a 5-year disease-free survival of 53% (95% CI, 34%-72%).
  • CONCLUSIONS: The prognosis of adult patients with acute lymphoblastic leukemia who relapse is poor.
  • Those aged less than 30 years with a first complete remission lasting longer than 2 years have reasonable possibilities of becoming long-term survivors while patients over this age or those who relapse early cannot be successfully rescued using the therapies currently available.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasm Recurrence, Local / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Remission Induction. Risk Factors. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix [11147225.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1843-9 [18398150.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Cancer Treat Rev. 2003 Feb;29(1):3-10 [12633575.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Biometrics. 1973 Sep;29(3):579-84 [4793138.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):896-903 [9217194.001]
  • [Cites] Leuk Lymphoma. 1997 May;25(5-6):579-83 [9250830.001]
  • [Cites] Haematologica. 1998 Mar;83(3):222-30 [9573676.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1216-30 [10506707.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1509-16 [16034462.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1346-56 [16219571.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):748-56 [16470520.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] Eur J Haematol. 2007 Feb;78(2):102-10 [17087744.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):163-205 [11253606.001]
  • (PMID = 20145276.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2857188
  • [Investigator] Ribera JM; Oriol A; Vives S; Feliu E; Hernández-Rivas JM; San Miguel JF; Tormo M; Terol MJ; Heras MI; Bernal T; Martínez-Revuelta E; Fuster J; Esteve J; Calvo C; Carboné A; Brunet S; Sierra J; Bergua JL; Marín J; Egurbide I; Sánchez J; García-Boyero R; Pérez de Oteyza J; Sarrà J; Bueno J; Ortega JJ; Bastida MP; Olivé T; Pérez-Hurtado JM; Parody R; González-Valentín ME; Rivas C; Fernández-Abellán P; Sanz MA; Moscardó F; Montesinos P; del Potro E; Díaz-Mediavilla J; Guinea JM; Guardia R; Martí JM; Vall-llobera F; Poderós C; Queizán JA; Martínez J; Bethencourt C; Maldonado J; Martín-Reina V; Gil JL; Moreno MJ; Ortega-Rivas F; Rodríguez JA; Moro MJ; Molinés A; Lodos V; Macià J; Novo A; Besalduch J; Pedro C; Abella E; Deben G; Casanova F; Gámez F; Alcalá A; Arias J; León P; Ares A; Llorente A; Atutxa K; Hernández-Nieto L; Díaz-Morfa G; Vivancos P; Rodríguez-Villa A; Bello JL; Carbonell F; Orts M; Fernández-Calvo J; Borrego D; Grande C
  •  go-up   go-down


48. Kamdem LK, Hamilton L, Cheng C, Liu W, Yang W, Johnson JA, Pui CH, Relling MV: Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet Genomics; 2008 Jun;18(6):507-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.
  • OBJECTIVE: Glucocorticoids are used universally in the remission induction therapy for acute lymphoblastic leukemia (ALL).
  • Hypertension was defined according to the guidelines of the American Academy of Pediatrics; patients were evaluated during the 28-day period of prednisone at 40 mg/m2/day during remission induction of childhood ALL.
  • RESULTS: Of the 602 children with newly diagnosed ALL who were normotensive pretherapy, 270 (45%) developed hypertension during remission induction.
  • CONCLUSION: Hypertension is common during ALL remission induction and is related to germline genetic variation.
  • [MeSH-major] Glucocorticoids / adverse effects. Hypertension / chemically induced. Hypertension / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Cytochrome P-450 CYP3A. Cytochrome P-450 Enzyme System / genetics. Female. Genetic Predisposition to Disease. Genotype. Humans. Infant. Male. Pharmacogenetics. Polymorphism, Genetic. Polymorphism, Single Nucleotide. Regression Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827853880 for PMID:18496130 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496130.001).
  • [ISSN] 1744-6872
  • [Journal-full-title] Pharmacogenetics and genomics
  • [ISO-abbreviation] Pharmacogenet. Genomics
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA070089; United States / NCI NIH HHS / CA / CA 36401; United States / NCI NIH HHS / CA / CA 51001; United States / NCI NIH HHS / CA / T32-CA070089; United States / NIGMS NIH HHS / GM / U01GM61374; United States / NCI NIH HHS / CA / CA21765; United States / NIGMS NIH HHS / GM / U01 GM61393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / CYP3A protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  •  go-up   go-down


49. Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, Franklin IM, Tallman MS, Cook L, Buck G, Durrant IJ, Rowe JM, Goldstone AH, Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood; 2006 Jul 15;108(2):465-72
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
  • Outcome of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) disease at diagnosis is unclear.
  • Patients up to 50 years old in first remission (CR1) with a matched related donor (MRD) underwent an allogeneic stem cell transplantation (SCT); the remainder in CR1 were randomized to an autologous SCT or intensive consolidation followed by maintenance chemotherapy.
  • Seventy-seven of 1508 (5%) patients a median age of 29 years had CNS leukemia at presentation; 13 of the 77 (17%) had Ph-positive ALL.
  • CNS leukemia in adult ALL is uncommon at diagnosis.
  • Adult Ph-negative ALL patients, however, can attain long-term disease-free survival using SCT as well as conventional chemotherapy.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Br J Haematol. 1994 Sep;88(1):94-100 [7803263.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):70-82 [9045306.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2017-25 [10811665.001]
  • [Cites] Leukemia. 2001 Feb;15(2):208-16 [11236936.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2464-71 [12011123.001]
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):40-6 [14695849.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Med Pediatr Oncol. 1986;14(3):191-4 [3528788.001]
  • [Cites] Blood. 1987 Apr;69(4):1015-20 [3548841.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):1014-30 [3163722.001]
  • [Cites] Blood. 1989 Jan;73(1):57-63 [2642717.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2814-22 [1835410.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:175-7 [1578926.001]
  • [Cites] Leukemia. 1992 Nov;6 Suppl 4:49-51 [1434832.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):314-9 [8321259.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1990-2001 [8410124.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2091-7 [7662956.001]
  • (PMID = 16556888.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA14548; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC1895498
  •  go-up   go-down


50. Liu Z, Liu XL, Du QF, Xu N, Zhong M, Song LL, Yi ZS, Liu QF, Meng FY, Zhou SY: [Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar;29(3):512-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL].
  • OBJECTIVE: To study the clinical characteristics and outcomes of BCR/ABL-positive acute lymphoblastic leukemia (BCR/ABL360888725-ALL) and screen the prognostic factors for BCR/ABL360888725-ALL.
  • RESULTS: Of the 59 patients, 32 (58.3%) achieved complete remission (CR) after the first induction cycle.
  • According to the FAB classification, 56 cases were divided into L1, L2 and biphenotypic acute leukemia (BAL) subgroups, and their CR rates were 66.7% (6/9), 63.2% (24/38) and 22.2% (2/9) (P=0.029), with OSs of 2-yrs of 22.2%, 27.0% and 22.0%, respectively (P=0.623).
  • In terms of immunophenotype grouping by EGIL, the patients with ALL, myeloid antigen-positive ALL and BAL had CR rates of 61.1% (11/18), 60.6% (20/33) and 12.5% (1/8) (P=0.039), and the OSs of 2-yrs of 22.7%, 21.0% and 18.8%, respectively (P=0.643).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Genes, abl / genetics. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Benzamides. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304540.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


51. Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Kim CC: Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia; 2009 Oct;23(10):1763-70
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
  • The aim of this prospective study was to investigate the feasibility of reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) in 37 adults with high-risk acute lymphoblastic leukemia (ALL) in first (n=30) or second (n=7) complete remission (CR).
  • The cumulative incidence of acute (grades II-IV) and chronic GVHD was 43.2 and 65.6%, respectively.
  • After a median follow-up of 36 months for surviving transplants, the 3-year relapse, non-relapse mortality, disease-free survival and overall survival rates were 19.7, 17.7, 62.6 and 64.1%, respectively.
  • This study suggests that RIC-SCT is a potential therapeutic approach for adults with high-risk ALL in remission who are ineligible for myeloablative transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Feasibility Studies. Female. Graft Survival. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Male. Melphalan / administration & dosage. Middle Aged. Prospective Studies. Remission Induction. Risk Factors. Survival Rate. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440217.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


52. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, Réa D, Cayuela JM, Vekemans MC, Reman O, Buzyn A, Pigneux A, Escoffre M, Chalandon Y, MacIntyre E, Lhéritier V, Vernant JP, Thomas X, Ifrah N, Dombret H, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL): Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood; 2007 Feb 15;109(4):1408-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
  • The combination of imatinib with chemotherapy has been recently reported as very promising in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
  • During 2004 and 2005, 45 patients with newly diagnosed Ph+ ALL were treated in the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAAPH) 2003 study, in which imatinib was started with HAM (mitoxantrone with intermediate-dose cytarabine) consolidation in good early responders (corticosensitive and chemosensitive ALL) or earlier during the induction course in combination with dexamethasone and vincristine in poor early responders (corticoresistant and/or chemoresistant ALL).
  • Overall, complete remission (CR) and BCR-ABL real-time quantitative polymerase chain reaction (RQ-PCR) negativity rates were 96% and 29%, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Philadelphia Chromosome. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Benzamides. Cytarabine / therapeutic use. Female. Hematopoietic Stem Cell Transplantation. Humans. Imatinib Mesylate. Male. Middle Aged. Mitoxantrone / therapeutic use. Neoplasm, Residual. Remission Induction. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062730.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 04079A1RDZ / Cytarabine; 8A1O1M485B / Imatinib Mesylate; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


53. Jinnai I, Sakura T, Tsuzuki M, Maeda Y, Usui N, Kato M, Okumura H, Kyo T, Ueda Y, Kishimoto Y, Yagasaki F, Tsuboi K, Horiike S, Takeuchi J, Iwanaga M, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Ohno R: Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study. Int J Hematol; 2010 Oct;92(3):490-502
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study.
  • We designed a treatment protocol for newly diagnosed adult acute lymphoblastic leukemia (ALL) in the pre-imatinib era, employing intensified consolidation therapy with a total of 330 mg/m² doxorubicin and adopting slightly modified induction and maintenance regimen of the CALGB 8811 study.
  • Of 404 eligible patients (median age 38 years, range 15-64 years), 298 (74%) achieved complete remission (CR).
  • The present treatment regimen could not show a better outcome than that of our previous JALSG-ALL93 study for adult ALL.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Female. Hematopoietic Stem Cell Transplantation. Humans. Japan. Male. Middle Aged. Philadelphia Chromosome. Prognosis. Remission Induction. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20830614.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


54. Battisti V, Schetinger MR, Maders LD, Santos KF, Bagatini MD, Correa MC, Spanevello RM, do Carmo Araújo M, Morsch VM: Changes in acetylcholinesterase (AchE) activity in lymphocytes and whole blood in acute lymphoblastic leukemia patients. Clin Chim Acta; 2009 Apr;402(1-2):114-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in acetylcholinesterase (AchE) activity in lymphocytes and whole blood in acute lymphoblastic leukemia patients.
  • BACKGROUND: Acute lymphoblastic leukemia (ALL) is a type of cancer that affects lymphocytes and it is the most common form of cancer in children.
  • Acetylcholinesterase (AChE) is well known as having non-cholinergic functions and has been detected in the blood and plasma of humans including in lymphocytes.
  • METHODS: This study was performed on 72 children with ALL divided into 4 groups: newly diagnosed, remission induction, remission maintenance and out-of-treatment and one control group of 50 healthy subjects.
  • RESULTS: Results demonstrated that whole blood AChE activity was enhanced in the newly diagnosed group and reduced in the remission induction and remission maintenance groups in relation to the control group.
  • For lymphocyte AChE activity we found an increase in the newly diagnosed group and a decrease in the remission induction group in relation to the control.
  • [MeSH-major] Acetylcholinesterase / blood. Lymphocytes / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / pharmacology. Child. Child, Preschool. Cytarabine / pharmacology. Female. Humans. Male. Methotrexate / pharmacology. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185568.001).
  • [ISSN] 1873-3492
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; EC 3.1.1.7 / Acetylcholinesterase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


55. Heesch S, Goekbuget N, Stroux A, Tanchez JO, Schlee C, Burmeister T, Schwartz S, Blau O, Keilholz U, Busse A, Hoelzer D, Thiel E, Hofmann WK, Baldus CD: Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica; 2010 Jun;95(6):942-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.
  • BACKGROUND: The role of the Wilms tumor 1 gene (WT1) in acute leukemias has been underscored by mutations found in acute myeloid leukemia identifying patients with inferior survival.
  • Furthermore, aberrant expression of WT1 in acute myeloid leukemia was associated with an increased risk of relapse.
  • No larger studies have performed a combined approach including WT1 mutation and expression analyses in acute T-lymphoblastic leukemia.
  • DESIGN AND METHODS: We analyzed the WT1 mutations and the expression status in a total of 252 consecutive adult patients with newly diagnosed T-lymphoblastic leukemia, who were registered on the GMALL 06/99 and 07/03 protocols and had sufficient material available.
  • The GMALL protocols included intensive chemotherapy as well as stem cell transplantation according to a risk-based model with indication for stem cell transplantation in first complete remission for early and mature T-lymphoblastic leukemia patients; patients with thymic T-lymphoblastic leukemia were allocated to a standard risk group and treated with intensive chemotherapy.
  • In thymic T-lymphoblastic leukemia, WT1mut patients had an inferior relapse-free survival compared to WT1 wild-type patients.
  • T-lymphoblastic leukemia patients with aberrant WT1 expression (high or negative) showed a higher relapse rate and an inferior outcome compared to patients with intermediate WT1 expression.
  • In the standard risk group of thymic T-lymphoblastic leukemia, aberrant WT1 expression was predictive for an inferior relapse-free survival as compared to patients with intermediate expression.
  • CONCLUSIONS: WT1 mutations were associated with an inferior relapse-free survival in standard risk thymic T-lymphoblastic leukemia patients.
  • Moreover, altered expression associated with inferior outcome also suggests a role of WT1 in T-lymphoblastic leukemia and the potential use of molecularly-based treatment stratification to improve outcome.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, Wilms Tumor / physiology. Mutation / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate / trends. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Leukemia. 1995 Jun;9(6):1060-7 [7596170.001]
  • [Cites] Exp Hematol. 1997 Apr;25(4):312-20 [9131006.001]
  • [Cites] Leukemia. 1997 May;11(5):639-43 [9180285.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1217-25 [9242555.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2961-8 [9531607.001]
  • [Cites] EMBO J. 1999 Jul 15;18(14):3990-4003 [10406804.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:80-97 [15561678.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1416-23 [15920493.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4414-5 [16326981.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Leukemia. 2006 Feb;20(2):254-63 [16341043.001]
  • [Cites] Haematologica. 2006 Feb;91(2):270-1 [16461320.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1507-15 [16575000.001]
  • [Cites] Oncogene. 2006 Jul 13;25(30):4217-29 [16518414.001]
  • [Cites] Leukemia. 2007 Mar;21(3):550-1; author reply 552 [17205055.001]
  • [Cites] Leukemia. 2007 May;21(5):868-76 [17361230.001]
  • [Cites] Expert Rev Mol Med. 2007;9(14):1-17 [17524167.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Leukemia. 2008 Apr;22(4):762-70 [18185524.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1154-60 [18368072.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1038-45 [19494353.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3303-12 [16380455.001]
  • [Cites] EMBO J. 2001 Apr 17;20(8):1897-909 [11296223.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1914-22 [11753613.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):409-20 [11841446.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):463-70 [12841384.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1589-95 [12886247.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Haematologica. 2004 Aug;89(8):926-33 [15339675.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1989 Apr;73(5):1247-58 [2467704.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):6198-206 [8119964.001]
  • [Cites] Hum Mutat. 1997;9(3):209-25 [9090524.001]
  • (PMID = 20435628.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2878792
  •  go-up   go-down


56. Nishiwaki S, Terakura S, Yasuda T, Imahashi N, Sao H, Iida H, Kamiya Y, Niimi K, Morishita Y, Kohno A, Yokozawa T, Ohashi H, Sawa M, Kodera Y, Miyamura K: Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission. Int J Hematol; 2010 Apr;91(3):419-25
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission.
  • The indication of allogeneic stem cell transplantation (allo-SCT) for Philadelphia chromosome-negative acute lymphocytic leukemia [Ph(-) ALL] from unrelated donors is not established.
  • To assess its potency of unrelated patients in first complete-remission (CR1) transplanted from unrelated donors and the potential prognostic factors affecting the probability of survival, we retrospectively analyzed a total of 41 adult Ph(-) ALL patients in CR1 who underwent unrelated bone marrow transplantation at 6 transplantation centers of the Nagoya Blood and Marrow Transplantation Group between 1993 and 2006.
  • Leukemia-free survival (LFS) at 3 and 6 years from allo-SCT was 60.3 and 47.7%, respectively.
  • Our study suggested that unrelated allo-SCT could improve LFS of patients with a potential graft-versus-leukemia effect.
  • [MeSH-major] Bone Marrow Transplantation / immunology. Histocompatibility / immunology. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Graft vs Host Disease / immunology. Graft vs Host Disease / mortality. Humans. Incidence. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Tissue Donors. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146028.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Reman O, Pigneux A, Huguet F, Vey N, Delannoy A, Fegueux N, de Botton S, Stamatoullas A, Tournilhac O, Buzyn A, Charrin C, Boucheix C, Gabert J, Lhéritier V, Vernant JP, Fière D, Dombret H, Thomas X, GET-LALA group: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. Leuk Res; 2008 Nov;32(11):1741-50
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group.
  • Outcome of adult acute lymphoblastic leukemia (ALL) with central nervous system (CNS) involvement is not clearly defined.
  • Eighty-seven patients (84%) with CNS leukemia at diagnosis achieved complete remission (CR).
  • CNS leukemia in adult ALL is uncommon at diagnosis as well as at the time of first relapse.
  • With intensification therapy, patients with CNS leukemia at diagnosis have a similar outcome than those who did not present with CNS involvement.
  • CNS leukemia at first relapse remains of similar poor prognosis than all other adult ALL in first relapse.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Neoplasm Recurrence, Local / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Incidence. Male. Middle Aged. Prognosis. Remission Induction. Stem Cell Transplantation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18508120.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


58. Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A, Pane F, Saglio G, Cimino G, Tafuri A, Meloni G, Fabbiano F, Recchia A, Kropp MG, Krampera M, Cascavilla N, Ferrara F, Romano A, Mazza P, Fozza C, Paoloni F, Vignetti M, Foà R: Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood; 2006 Jan 15;107(2):473-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol.
  • Between 1996 and 2000, 90 newly diagnosed adult patients with T-acute lymphoblastic leukemia (T-ALL) were registered in the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Leucemia Acuta Limfoide (LAL) 0496 protocol.
  • Fifty-six percent of patients with pro-T + pre-T-ALL achieved complete remission (CR) compared with 91% for cortical + mature cases (P = .002).
  • An extensive biologic workup of adult T-ALL cases at presentation is recommended in order to design tailored therapeutic strategies aimed at improving CR rates.
  • [MeSH-major] Chromosome Aberrations. Leukemia-Lymphoma, Adult T-Cell. Oncogene Proteins, Fusion / metabolism. P-Glycoprotein / metabolism
  • [MeSH-minor] Adolescent. Adult. Cytogenetic Analysis. Drug Resistance, Multiple. Female. Humans. Immunophenotyping. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Prognosis. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179376.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / P-Glycoprotein
  •  go-up   go-down


59. Labar B, Suciu S, Willemze R, Muus P, Marie JP, Fillet G, Berneman Z, Jaksic B, Feremans W, Bron D, Sinnige H, Mistrik M, Vreugdenhil G, De Bock R, Nemet D, Gilotay C, Amadori S, de Witte T, EORTC Leukemia Group: Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica; 2010 Sep;95(9):1489-95
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.
  • BACKGROUND: Corticosteroids are a standard component of the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.
  • DESIGN AND METHODS: Adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma were randomized to receive, as part of their induction therapy on days 1-8 and 15-22, either dexamethasone 8 mg/m(2) or prednisolone 60 mg/m(2).
  • Those who reached complete remission were given two courses of consolidation therapy with high-dose cytarabine and mitoxantrone and methotrexate and asparaginase.
  • After induction and the course of first consolidation therapy, 131 (80.4%) patients in the dexamethasone group and 124 (76.5%) in the prednisolone group achieved complete remission.
  • Disease-free survival after complete remission was also similar in the dexamethasone and prednisolone groups, the 6-year rates being 32.3% and 37.5%, respectively (hazard ratio 1.03; 95% confidence interval 0.76-1.40).
  • CONCLUSIONS: In the ALL-4 trial in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, treatment with dexamethasone did not show any advantage over treatment with prednisolone.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1986 Mar 20;314(12):729-35 [3513012.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Jun;40(6):1073-7 [1133157.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):269-75 [2056971.001]
  • [Cites] Bone Marrow Transplant. 1994 Nov;14(5):767-74 [7889010.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):1-12 [7743230.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):911-8 [8622039.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):114-21 [8649318.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2370-6 [8708730.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):734-45 [15952999.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Leukemia. 2007 Apr;21(4):593-4 [17301807.001]
  • [Cites] Semin Hematol. 2007 Oct;44(4):267-73 [17961726.001]
  • [Cites] Health Qual Life Outcomes. 2008;6:103 [19036151.001]
  • [Cites] Pediatr Blood Cancer. 2009 Dec;53(6):984-91 [19621425.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Leukemia. 2000 Mar;14(3):356-63 [10720126.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1964-9 [10760775.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix [11147225.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2193-4 [11187910.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Apr-May;18(3):187-91 [11293286.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2898-903 [12767105.001]
  • [Cites] Haematologica. 2004 Jul;89(7):809-17 [15257932.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):202-7 [3806166.001]
  • (PMID = 20378563.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / CA11488-25; United States / NCI NIH HHS / CA / CA11489-39
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone
  • [Other-IDs] NLM/ PMC2930949
  •  go-up   go-down


60. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, Chevallier P, Buzyn A, Delannoy A, Chalandon Y, Vernant JP, Lafage-Pochitaloff M, Chassevent A, Lhéritier V, Macintyre E, Béné MC, Ifrah N, Dombret H: Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol; 2009 Feb 20;27(6):911-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.
  • PURPOSE: Retrospective comparisons have suggested that adolescents or teenagers with acute lymphoblastic leukemia (ALL) benefit from pediatric rather than adult chemotherapy regimens.
  • Thus, the aim of the present phase II study was to test a pediatric-inspired treatment, including intensified doses of nonmyelotoxic drugs, such as prednisone, vincristine, or L-asparaginase, in adult patients with ALL up to the age of 60 years.
  • PATIENTS AND METHODS: Between 2003 and 2005, 225 adult patients (median age, 31 years; range, 15 to 60 years) with Philadelphia chromosome-negative ALL were enrolled onto the Group for Research on Adult Acute Lymphoblastic Leukemia 2003 protocol, which included several pediatric options.
  • Some adult options, such as allogeneic stem-cell transplantation for patients with high-risk ALL, were nevertheless retained.
  • RESULTS: were retrospectively compared with the historical France-Belgium Group for Lymphoblastic Acute Leukemia in Adults 94 (LALA-94) trial experience in 712 patients age 15 to 55 years.
  • Results Complete remission rate was 93.5%.
  • Complete remission rate (P = .02), EFS (P < .001), and OS (P < .001) compared favorably with the previous LALA-94 experience.
  • CONCLUSION: These results suggest that pediatric-inspired therapy markedly improves the outcome of adult patients with ALL, at least until the age of 45 years.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Patient Selection. Philadelphia Chromosome. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2009 May 20;27(15):2574. Dosage error in article text
  • (PMID = 19124805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


61. Wojnar J, Giebel S, Hołowiecka-Goral A, Krawczyk-Kuliś M, Markiewicz M, Stella-Hołowiecka B, Wylezoł I: [Impact of chronic graft-versus-host disease on long-term outcome after allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia]. Pol Arch Med Wewn; 2006 Jul;116(1):671-7
Genetic Alliance. consumer health - Chronic Graft versus Host Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of chronic graft-versus-host disease on long-term outcome after allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia].
  • However, it may be accompanied by graft-versus-leukemia (GVL) reaction contributing to decreased risk of relapse.
  • The aim of this study was to evaluate the influence of cGVHD on outcome of adult acute lymphoblastic leukemia (ALL) patients treated with alloHCT.
  • 24 patients 44% were given alloHCT in first complete remission, whereas the remaining 31 patients (44%) were in more advanced disease.
  • Cumulative incidence of relapse and non-relapse mortality (NRM) was 39% and 13%, respectively.
  • [MeSH-major] Graft vs Host Disease / epidemiology. Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Secondary Prevention. Survival Analysis. Tissue Donors. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17340974.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


62. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A: Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood; 2009 Apr 30;113(18):4153-62
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
  • Clinical risk classification is inaccurate in predicting relapse in adult patients with acute lymphoblastic leukemia, sometimes resulting in patients receiving inappropriate chemotherapy or stem cell transplantation (SCT).
  • Of 280 registered patients (236 in remission), 34 underwent an early SCT, 60 suffered from relapse or severe toxicity, and 142 were evaluable for MRD at the end of consolidation.
  • [MeSH-major] Neoplasm, Residual / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Oncogene Proteins, Fusion / genetics. Prognosis. Prospective Studies. Risk Factors. Survival Rate. Translocation, Genetic. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141862.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00358072
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


63. Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, Parody R, Deben G, Bello JL, Feliu E, Programa para el Estudio y Tratamiento de Hemopatias Malignas Group: Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer; 2006 Jun 15;106(12):2540-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
  • Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) confers a poor prognosis, although to the authors' knowledge, only a few studies have analyzed this issue in adults.
  • For the current study, the authors analyzed the frequency, predictive factors, and prognosis of CNS involvement and recurrence in adult patients with ALL who did not receive cranial irradiation for CNS prophylaxis.
  • Four hundred sixty-seven adult patients (age > or = 15 years) with ALL were treated on 4 protocols: ALL-89 (standard-risk and high-risk ALL; n = 108 patients), ALL-93 (high-risk ALL; n = 222 patients), ALL-96 (standard-risk ALL; n = 84 patients), and ALL3-97 (Burkitt leukemia; n = 53 patients).
  • A complete remission was attained in 7 of 22 patients (32%).
  • The frequency of CNS recurrence in adult patients with ALL who do not receive radiotherapy for CNS prophylaxis was similar to the frequency observed in protocols that included cranial irradiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Incidence. Lactate Dehydrogenases / analysis. Male. Methotrexate / administration & dosage. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16700036.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 1.1.- / Lactate Dehydrogenases; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


64. Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, Razzouk BI, Ribeiro RC, Rubnitz JE, Sandlund JT, Rivera GK, Evans WE, Relling MV, Pui CH: Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA; 2007 Mar 21;297(11):1207-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia.
  • CONTEXT: Little is known about the incidence of secondary neoplasms after 15 to 20 years in children and adolescents who were treated for acute lymphoblastic leukemia.
  • OBJECTIVES: To investigate the cumulative incidence of secondary neoplasms in pediatric patients treated for acute lymphoblastic leukemia over 30 years and to characterize late-occurring tumors.
  • DESIGN, SETTING, AND PATIENTS: Retrospective study of 2169 patients with acute lymphoblastic leukemia treated between 1962 and 1998 at St Jude Children's Research Hospital, Memphis, Tenn, who achieved complete remission and had a median follow-up time of 18.7 years (range, 2.4-41.3 years).
  • MAIN OUTCOME MEASURES: Cumulative incidences of secondary neoplasms in first remission and standard incidence ratios of observed rates compared with rates of cancer development in the general US population.
  • RESULTS: Secondary neoplasms developed as the first event in 123 patients and comprised 46 myeloid malignancies, 3 lymphomas, 14 basal cell carcinomas, 16 other carcinomas, 6 sarcomas, 16 meningiomas, and 22 other brain tumors.
  • The cumulative incidence of each tumor type at 30 years was 2.19% (SE, 0.32%) for myeloid malignancy, 0.17% (SE, 0.10%) for lymphoma, 3.00% (SE, 0.59%) for brain tumor, 4.91% (SE, 1.04%) for carcinoma, and 0.57% (SE, 0.37%) for sarcoma.
  • CONCLUSIONS: The cumulative incidence of secondary neoplasms increases steadily over 30 years after treatment of acute lymphoblastic leukemia.
  • These results suggest that lifelong follow-up of acute lymphoblastic leukemia survivors is needed to ascertain the full impact of treatment and other leukemia-related factors on secondary neoplasm development.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374815.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-36401; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA-60419; United States / NCI NIH HHS / CA / CA-71907; United States / NCI NIH HHS / CA / CA-78224; United States / NIGMS NIH HHS / GM / GM-61393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Jin FY, Zou DH, Wang GR, Xu Y, Feng SZ, Zhao YZ, Han MZ, Yan WW, Qiu LG: [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients]. Zhonghua Xue Ye Xue Za Zhi; 2005 Nov;26(11):645-8
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
  • OBJECTIVE: To evaluate the effectiveness of chemotherapy (CT) and autologous hematopoietic stem cell transplantation (ASCT) as post-remission treatment for adult acute lymphoblastic leukemia (AL) patients.
  • METHODS: Seventy-four ALL patients achieved first complete remission (CR(1)) with induction therapy, and then received early-stage sequential intensive consolidation chemotherapy.
  • After that, 40 patients received chemotherapy (CT group) and 34 received ASCT (ASCT group) as post-remission treatment.
  • The rates of leukemia free survival (LFS), overall survival (OS) and relapse were compared between the two groups. RESULTS:.
  • CONCLUSIONS: Early sequential intensive consolidation chemotherapy followed by auto-HSCT could significantly reduce late relapse rate for adult ALL patients, and those received ex vivo purged autografts and immunotherapy and (or) maintenance therapy after ASCT have lower late relapse rate and superior survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620547.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


66. Maury S, Huguet F, Leguay T, Lacombe F, Maynadié M, Girard S, de Labarthe A, Kuhlein E, Raffoux E, Thomas X, Chevallier P, Buzyn A, Delannoy A, Chalandon Y, Vernant JP, Rousselot P, Macintyre E, Ifrah N, Dombret H, Béné MC, Group for Research on Adult Acute Lymphoblastic Leukemia: Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica; 2010 Feb;95(2):324-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.
  • The prognostic significance of CD20 expression in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has been mostly studied in children and yielded conflicting results.
  • While not influencing complete remission achievement, CD20 expression was associated with a higher cumulative incidence of relapse (CIR) at 42 months (P=0.04), independently of the ALL high-risk subset (P=0.025).
  • CD20 expression thus appears to be associated with a worse outcome, which reinforces the interest of evaluating rituximab combined to chemotherapy in CD20-positive adult BCP-ALL.
  • [MeSH-major] Antigens, CD20 / genetics. Gene Expression. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Clinical Trials as Topic. Humans. Leukocyte Count. Middle Aged. Philadelphia Chromosome. Prognosis. Recurrence. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(2):225-7 [11281397.001]
  • [Cites] Blood. 2009 Jun 18;113(25):6330-7 [18703706.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):316-21 [12042706.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Apr;25(4):327-9 [12679650.001]
  • [Cites] Ann Hematol. 2004 Apr;83(4):201-5 [14648023.001]
  • [Cites] Stat Med. 1988 Mar;7(3):435-41 [3358023.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3960-6 [9166833.001]
  • [Cites] Leukemia. 1999 May;13(5):679-86 [10374870.001]
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] Haematologica. 2005 Nov;90 Suppl:ECR24 [16266915.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Haematologica. 2006 Feb;91(2):272-3 [16461321.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3302-4 [16896151.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):117-25 [18457327.001]
  • [Cites] Blood. 2008 Nov 15;112(10):3982-8 [18780832.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):64-75 [19100369.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):911-8 [19124805.001]
  • [CommentIn] Haematologica. 2010 Jun;95(6):1040-2; author reply 1042 [20107157.001]
  • (PMID = 19773266.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00222027
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD20
  • [Other-IDs] NLM/ PMC2817037
  •  go-up   go-down


67. Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H, Fukuda T, Ozawa Y, Kobayashi N, Kasai M, Mori T, Iwato K, Yoshida T, Onizuka M, Kawa K, Morishima Y, Suzuki R, Atsuta Y, Miyamura K: Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood; 2010 Nov 18;116(20):4368-75
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission.
  • To identify factors to improve the outcomes of related and unrelated allogeneic stem cell transplantations (allo-SCT) for Philadelphia chromosome-negative acute lymphocytic leukemia (Ph(-) ALL) in the first complete remission (CR1), we retrospectively analyzed 1139 Ph(-) ALL patients using the registry data, particularly the details of 641 patients transplanted in CR1.
  • After a close consideration of these factors, the outcome of allo-SCT for adult Ph(-) ALL in CR1 could be improved.
  • [MeSH-major] Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Humans. Middle Aged. Multivariate Analysis. Recurrence. Remission Induction. Risk Factors. Survival Rate. Tissue Donors. Transplantation, Homologous. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664060.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Zhou PY, Li WJ, Wei CX, Zhou Z: [Expression of PRAME gene in adult acute leukemia and its significance in prognosis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec;15(6):1177-81
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of PRAME gene in adult acute leukemia and its significance in prognosis].
  • The study was aimed to investigate the expression of preferentially expressed antigen of melanoma (PRAME) gene in adult acute leukemia and its clinical significance.
  • The expression of the PRAME gene of bone marrow was measured by reverse transcriptase polymerase chain reaction (RT-PCR) in 73 adult newly diagnosed acute leukemia patients, 3 relapsed patients, 7 patients with idiopathic thrombocytopenic purpura (ITP) and 8 healthy donors, as well as two AL cell-lines (K562 and U937).
  • The results indicated that PRAME mRNA was expressed in 42.9% AML patients (n=24) and 20% ALL patients (n=4), also in two leukemia cell-lines K562 and U937, but not in eight health donors and seven ITP patients.
  • PRAME mRNA expression in complete remission group seems much higher than those in partial complete remission group and death group.
  • PRAME gene was overexpressed in adult acute leukemia patients and leukemia cell-lines.
  • It is concluded that the expression of PRAME is an indicator of favorable prognosis and can be a useful tool for monitoring minimal residual disease (MRD) in adult acute leukemia.
  • Differential expression between adult acute leukemia patients and healthy volunteers suggests that the immunogenic antigens PRAME are potential candidates for immunotherapy in adult acute leukemia.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088461.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / PRAME protein, human; 0 / RNA, Messenger
  •  go-up   go-down


69. Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan AK, Litzow MR, Lazarus HM, Foroni L, Dewald G, Franklin IM, Luger SM, Paietta E, Wiernik PH, Tallman MS, Goldstone AH: Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood; 2009 May 07;113(19):4489-96
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.
  • Prospective data on the value of allogeneic hematopoietic stem cell transplantation (alloHSCT) in Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) are limited.
  • The UKALLXII/ECOG 2993 study evaluated the outcome of assigning alloHSCT with a sibling (sib) or matched unrelated donor (MUD) to patients younger than 55 years of age achieving complete remission (CR).
  • This prospective trial in adult Ph(+) ALL indicates a modest but significant benefit to alloHSCT.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Philadelphia Chromosome. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Benzamides. Female. Humans. Imatinib Mesylate. Immunophenotyping. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Prognosis. Prospective Studies. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. RNA, Messenger / genetics. RNA, Messenger / metabolism. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1991 Mar;5(3):196-9 [2013979.001]
  • [Cites] Blood. 1987 Aug;70(2):587-8 [3300815.001]
  • [Cites] Am J Med. 1994 Jul;97(1):60-5 [8030658.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Bone Marrow Transplant. 1995 Nov;16(5):663-7 [8547863.001]
  • [Cites] Blood. 2005 Jul 15;106(2):458-63 [15817679.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1410-4 [9269758.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):365-9 [8704688.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):489-500 [16098062.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Ann Hematol. 2006 Jun;85(6):366-73 [16523310.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Cancer. 2007 May 15;109(10):2068-76 [17429836.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2309-15 [17496201.001]
  • [Cites] Haematologica. 2008 Feb;93(2):287-90 [18223280.001]
  • [Cites] Haematologica. 2008 Feb;93(2):303-6 [18245655.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Blood. 2008 Aug 1;112(3):903-9 [18519812.001]
  • [Cites] Blood. 2009 Jan 1;113(1):100-7 [18838613.001]
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):263-73 [10674898.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1536-43 [11861265.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] Bone Marrow Transplant. 2003 May;31(9):763-6 [12732882.001]
  • [Cites] Br J Haematol. 2004 Feb;124(3):275-88 [14717774.001]
  • [Cites] Blood. 1987 Apr;69(4):1015-20 [3548841.001]
  • [Cites] Blood. 1992 Jun 1;79(11):3067-70 [1586748.001]
  • (PMID = 19244158.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN77346223; ClinicalTrials.gov/ NCT00002514
  • [Grant] United Kingdom / Medical Research Council / / MRC/ MC/ U137686856; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U24 CA114737
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC4188540
  •  go-up   go-down


70. Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C, Picardi M, Specchia G, Mancini M, Cuneo A, Mecucci C, Martinelli G, Saglio G, Rotoli B, Mandelli F, Salvatore F, Foà R, GIMEMA group: Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia; 2005 Apr;19(4):628-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
  • Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has a dismal prognosis.
  • We prospectively evaluated minimal residual disease (MRD) by measuring BCR/ ABL levels with a quantitative real-time PCR procedure after induction and after consolidation in 45 adults with Ph+ ALL who obtained complete hematological remission after a high-dose daunorubicin induction schedule.
  • A total of 42 patients evaluable for outcome analysis were operationally divided into two MRD groups: good molecular responders (GMRs; n = 28) with > 2 log reduction of residual disease after induction and > 3 log reduction after consolidation therapy, and poor molecular responders (PMRs; n = 14) who, despite complete hematological remission, had a higher MRD at both time points.
  • Salvage therapy induced a second sustained complete hematological remission in three GMR patients, but in no PMR patient.
  • Our data indicate that, as already shown in children, adult Ph+ ALL patients have a heterogeneous sensitivity to treatment, and that early quantification of residual disease is a prognostic parameter in this disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fusion Proteins, bcr-abl / genetics. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Asparaginase / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual / drug therapy. Neoplasm, Residual / genetics. Neoplasm, Residual / mortality. Predictive Value of Tests. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744351.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


71. Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhéritier V, Vernant JP, Dombret H, Thomas X, GET-LALA Group, Swiss Group for Clinical Cancer Research SAKK, Australasian Leukaemia and Lymphoma Group: Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia; 2007 Sep;21(9):1907-14
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.
  • Fifty-four percent of adults with acute lymphoblastic leukemia (ALL) who entered the LALA-94 trial experienced a first relapse.
  • We examined the outcome of these 421 adult patients.
  • One hundred and eighty-seven patients (44%) achieved a second complete remission (CR).
  • We conclude that most adult patients with recurring ALL could not be rescued using current available therapies, although allogeneic SCT remains the best therapeutic option.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Disease-Free Survival. Feasibility Studies. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Risk Factors. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611565.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


72. Lee S, Cho BS, Kim SY, Choi SM, Lee DG, Eom KS, Kim YJ, Kim HJ, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Shin WS, Kim CC: Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant; 2007 Sep;13(9):1083-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.
  • The aim of the present study was to identify graft-versus-leukemia effects and the factors that affect outcome in 201 adults with acute lymphobalstic leukemia who received myeloablative allogeneic stem cell transplantation from matched sibling or unrelated donors (1995-2004).
  • One hundred seventy-eight (88.6%) of these patients had high-risk criteria, and 151 (75.1%) patients were transplanted in first complete remission (CR).
  • [MeSH-major] Graft vs Host Disease / drug therapy. Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Data Collection. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Myeloablative Agonists / therapeutic use. Premedication. Prognosis. Remission Induction. Retrospective Studies. Tissue Donors. Translocation, Genetic. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697971.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists
  •  go-up   go-down


73. Trebo MM, Attarbaschi A, Mann G, Minkov M, Kornmüller R, Gadner H: Histiocytosis following T-acute lymphoblastic leukemia: a BFM study. Leuk Lymphoma; 2005 Dec;46(12):1735-41
Genetic Alliance. consumer health - Histiocytosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histiocytosis following T-acute lymphoblastic leukemia: a BFM study.
  • The coincidence of T-cell acute lymphoblastic leukemia (T-ALL) and histiocytic disorders, including hemophagocytic lymphohistiocytosis (T-ALL/HLH) and Langerhans cell histiocytosis (T-ALL/LCH), is very seldom and is usually associated with a dismal prognosis.
  • The mean initial leukocyte count was higher than in the non-HLH/LCH group (270,700 +/- 60,677 microl(-1) vs 134,141 +/- 5,663 microl(-1); p = 0.074).
  • Five of 6 patients obtained a good prednisone response (GPR) at day 8 in peripheral blood with <5% blasts at day 15 in BM and all cases were in complete remission (CR) at day 33.
  • [MeSH-major] Histiocytosis / etiology. Leukemia-Lymphoma, Adult T-Cell / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263575.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Fouillard L, Labopin M, Gratwohl A, Gluckman E, Frassoni F, Beelen DW, Willemze R, Montserrat E, Blaise D, Atienza AI, Sierra J, Santos M, Gorin NC, Rocha V, Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation: Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. Haematologica; 2008 Jun;93(6):834-41
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
  • BACKGROUND: The possibility of performing syngeneic hematopoietic stem cell transplantation is rare and there are concerns about the absence of a graft-versus-leukemia effect following such a strategy.
  • We report the outcomes of a large series of adult patients who underwent syngeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia or acute lymphoblastic leukemia.
  • DESIGN AND METHODS: The outcomes of all syngeneic transplants for acute myeloblastic or lymphoblastic leukemia reported to the European Group for Blood and Marrow Transplantation registry were analyzed; a study of prognostic factors was performed for those transplanted in first complete remission.
  • RESULTS: One hundred and sixty-two patients, 109 with acute myeloblastic leukemia and 53 with acute lymphoblastic leukemia, were identified; 116 were in first complete remission.
  • Nineteen patients developed acute graft-versus-host disease and only three patients developed chronic graft-versus-host disease.
  • At 5 years the non-relapse mortality was 8 +/- 5%, the relapse incidence 49 +/- 8% and the leukemia-free survival 43 +/- 3%.
  • The corresponding figures for patients in first complete remission were 7 +/- 2%, 40 +/- 4% and 53 +/- 5% at 5 years.
  • Analysis of patients in first complete remission showed that the number of courses of chemotherapy required to induce first complete remission was the main risk factor: the leukemia-free survival at 5 years was 66 +/- 6% when first complete remission was reached after one induction course of chemotherapy and was only 20 +/- 9% when first complete remission was reached after at least two induction courses of chemotherapy (p = 0.0001); the relapse incidence was 30 +/- 6% and 54 +/- 10%, respectively (p = 0.007).
  • CONCLUSIONS: Outcomes were better for patients transplanted in first complete remission than in second complete remission or a more advanced phase of the disease.
  • When a syngeneic donor is available for patients with high risk acute leukemia, allotransplantation should be performed as soon as the first complete remission has been achieved, ideally with one course of chemotherapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Diseases in Twins. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Recurrence. Remission Induction. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Jun;93(6):801-5 [18515876.001]
  • (PMID = 18469352.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


75. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Müller MC, Beneke H, Müller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Müller-Hermelink K, Hodges E, Whittaker SJ, Diecker F, Döhner H, Schuld P, Hehlmann R, Hochhaus A, Cross NC, Reiter A: Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia; 2007 Jun;21(6):1183-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
  • Here, we report on seven FIP1L1-PDGFRA-positive patients who presented with acute myeloid leukemia (AML, n=5) or lymphoblastic T-cell non-Hodgkin-lymphoma (n=2) in conjunction with AML or Eos-MPD.
  • AML patients were negative for common mutations of FLT3, NRAS, NPM1, KIT, MLL and JAK2; one patient revealed a splice mutation of RUNX1 exon 7.
  • All patients are alive, disease-free and in complete hematologic and complete molecular remission after a median time of 20 months (range, 9-36) on imatinib.
  • The median time to achievement of complete molecular remission was 6 months (range, 1-14).
  • We conclude that all eosinophilia-associated hematological malignancies should be screened for the presence of the FIP1L1-PDGFRA fusion gene as they are excellent candidates for treatment with tyrosine kinase inhibitors even if they present with an aggressive phenotype such as AML.
  • [MeSH-major] Eosinophilia / drug therapy. Leukemia, Myeloid / drug therapy. Oncogene Proteins, Fusion / analysis. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage. Receptor, Platelet-Derived Growth Factor alpha. mRNA Cleavage and Polyadenylation Factors
  • [MeSH-minor] Acute Disease. Adult. Aged. Benzamides. Disease-Free Survival. Humans. Imatinib Mesylate. Male. Middle Aged. Myeloproliferative Disorders / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors. Remission Induction / methods


76. Leung W, Neale G, Behm F, Iyengar R, Finkelstein D, Kastan MB, Pui CH: Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia. Cancer Epidemiol; 2010 Jun;34(3):303-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia.
  • BACKGROUND: Survivors of childhood acute lymphoblastic leukemia (ALL) are at an increased risk of developing secondary malignant neoplasms.
  • METHODS: Comparative studies on 14 survivors in first complete remission and 16 siblings were conducted.
  • In contrast, patients had lower numbers of all lymphocyte subsets involved in innate immunity (gammadeltaT cells and all NK subsets, including KIR2DL1+ cells, KIR2DL2/L3+ cells, and CD16+ cells), and lower natural cytotoxicity against K562 leukemia cells.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Blood. 2000 Jan 1;95(1):352-9 [10607724.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):41-9 [11905813.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1036-42 [10973325.001]
  • [Cites] Lancet. 2000 Nov 25;356(9244):1795-9 [11117911.001]
  • [Cites] Science. 2001 Oct 19;294(5542):605-9 [11567106.001]
  • [Cites] Nat Immunol. 2002 Jan;3(1):83-90 [11743585.001]
  • [Cites] Lancet. 1994 Jul 23;344(8917):224-7 [7913156.001]
  • [Cites] JAMA. 1994 Nov 9;272(18):1427-32 [7933424.001]
  • [Cites] Nature. 1995 May 11;375(6527):155-8 [7753173.001]
  • [Cites] Biochemistry. 1996 Jun 18;35(24):8035-44 [8672508.001]
  • [Cites] Blood. 2002 May 15;99(10):3661-7 [11986221.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Nat Biotechnol. 2003 Oct;21(10):1233-7 [12960966.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):644-50 [14688377.001]
  • [Cites] Genome Res. 2004 Feb;14(2):287-95 [14762065.001]
  • [Cites] Genome Res. 2004 Mar;14(3):414-25 [14993208.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4464-71 [15231655.001]
  • [Cites] Blood. 1972 Jul;40(1):42-51 [4624721.001]
  • [Cites] Cancer Res. 1982 Oct;42(10):4289-92 [6955009.001]
  • [Cites] Med Pediatr Oncol. 1986;14(6):295-9 [3466000.001]
  • [Cites] Lancet. 1987 Jan 24;1(8526):190-3 [2880018.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):136-42 [2787477.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):143-51 [2501681.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1348-56 [2072138.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] Biomed Pharmacother. 1996;50(3-4):125-31 [8881368.001]
  • [Cites] Immunol Rev. 1997 Dec;160:159-70 [9476674.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Mutat Res. 1998 Dec 3;422(2):213-22 [9838123.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):316-23 [15549093.001]
  • [Cites] Cell. 2005 Feb 25;120(4):497-512 [15734682.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6540-5 [15879158.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1749-54 [15920008.001]
  • [Cites] Nature. 2005 Aug 25;436(7054):1186-90 [15995699.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7936-41 [16258093.001]
  • [Cites] Curr Opin Immunol. 2006 Feb;18(1):31-8 [16337364.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):261-70 [16498454.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10672-7 [16807291.001]
  • [Cites] Semin Cancer Biol. 2006 Oct;16(5):344-7 [16914325.001]
  • [Cites] J Leukoc Biol. 2006 Oct;80(4):915-21 [16877676.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1717-22 [16888619.001]
  • [Cites] Nat Cell Biol. 2008 Jan;10(1):85-92 [18084281.001]
  • [Cites] Leukemia. 2000 Apr;14(4):567-72 [10764140.001]
  • (PMID = 20413363.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA021765-24; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / P30 CA-21765-24
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS193817; NLM/ PMC2874127
  •  go-up   go-down


77. Arteaga-Ortiz L, Buitrón-Santiago N, Rosas-López A, Rosas-Arzate G, Armengolt-Jiménez A, Aguayo A, López-Karpovitch X, Crespo-Solís E: [Acute lymphoblastic leukemia: experience in adult patients treated with hyperCVAD and 0195 Protocol, at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Cohort 2003-2007]. Rev Invest Clin; 2008 Nov-Dec;60(6):459-69
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia: experience in adult patients treated with hyperCVAD and 0195 Protocol, at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Cohort 2003-2007].
  • INTRODUCTION: Despite therapeutic advances, acute lymphoblastic leukemia (ALL) in adults remains a disease with poor long term outcome and survival rates.
  • OBJECTIVE: To describe characteristics of adults with acute lymphoblastic leukemia, response to treatment, complications and to evaluate further survival related factors and to compare our experience with other reports of literature.
  • There were 36 patients who received treatment: 13 received HCVAD and 23 the 0195 protocol; 78% achieved global complete remission, 85% for the patients with HCVAD and 74% with 0195.
  • Factors associated with worse survival rate were hyperleukocytosis, T phenotype and lack of early complete remission.
  • During induction, grade 3 to 4 non hematopoietic toxicity was 17%.
  • CONCLUSIONS: With HCVAD, we observed worse complete remission, disease-free survival and overall survival rates compared with the original MDACC reports.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibiotic Prophylaxis / utilization. Cohort Studies. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Leukocyte Count. Male. Mexico / epidemiology. Middle Aged. Platelet Transfusion. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Urban Population. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Invest Clin. 2009 Jan-Feb;61(1):90
  • (PMID = 19378832.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


78. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM: T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood; 2009 Dec 10;114(25):5136-45
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
  • The biology and outcome of adult T-cell acute lymphoblastic leukemia are poorly understood.
  • Complete remission was obtained in 94% of patients, and 48% survived 5 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation / methods. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Cytogenetic Analysis. Female. Fusion Proteins, bcr-abl / genetics. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prospective Studies. Remission Induction. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 2000 Sep 21;243(1-2):59-75 [10986407.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4352-6 [19635999.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Apr;16(2):245-99, v [12094473.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jan;127(1):42-8 [12521365.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Dec;16(4):671-83 [14592650.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Blut. 1990 Jan;60(1):48-51 [2297585.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Mar;52(1):79-84 [2009514.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1832-3 [8892689.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3931-9 [10339502.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3028-37 [15256423.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Blood. 2006 Jan 15;107(2):473-9 [16179376.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):989-95 [16633362.001]
  • [Cites] Blood. 2006 Jul 15;108(2):465-72 [16556888.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Leukemia. 2007 Apr;21(4):622-6 [17301806.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Nature. 2008 Apr 10;452(7188):764-7 [18401411.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):153-68 [18691165.001]
  • [Cites] Blood. 2009 Jan 1;113(1):100-7 [18838613.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [Cites] Haematologica. 2001 Jul;86(7):675-92 [11454522.001]
  • (PMID = 19828704.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G8223452; United Kingdom / Medical Research Council / / MRC/ MC/ U137686856; United States / NCI NIH HHS / CA / R01CA120196; United Kingdom / Medical Research Council / / MRC/ G0500389; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / R01 CA120196-03
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Other-IDs] NLM/ PMC2792210
  •  go-up   go-down


79. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML: Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol; 2010 Feb 1;28(4):648-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.
  • PURPOSE: Despite improvements in treatment, approximately 20% of patients with acute lymphoblastic leukemia (ALL) experience relapse and do poorly.
  • The Therapeutic Advances in Childhood Leukemia (TACL) Consortium was assembled to assess novel drugs for children with resistant leukemia.
  • We hypothesize that novel agents and combinations that fail to improve baseline complete remission rates in comparable populations are unlikely to contribute to better outcomes and should be abandoned.
  • RESULTS: Complete remission (CR) rates (mean +/- SE) were 83% +/- 4% for early first marrow relapse, 93% +/- 3% for late first marrow relapse, 44% +/- 5% for second marrow relapse, and 27% +/- 6% for third marrow relapse.
  • CONCLUSION: We generally confirm a 40% CR rate for second and subsequent relapse, but our remission rate for early first relapse seems better than that reported in the literature (83% v approximately 70%).
  • Our data may allow useful modeling of an expected remission rate for any population of patients who experience relapse.
  • [MeSH-major] Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Infant. Infant, Newborn. Male. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Jan 15;103(2):368-76 [15599932.001]
  • [Cites] Br J Haematol. 1998 Jul;102(2):423-38 [9695956.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4961-7 [16493003.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5750-62 [17179109.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5800-7 [18089878.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3971-8 [18711187.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2142-50 [18818707.001]
  • [Cites] Br J Haematol. 2009 Feb;144(4):559-70 [19077160.001]
  • [Cites] Leukemia. 2003 Oct;17(10):1967-72 [14513046.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] Lancet. 1987 Feb 21;1(8530):429-32 [2880224.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1166-72 [1878583.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]
  • [Cites] Med Pediatr Oncol. 1996 Dec;27(6):505-14 [8888809.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):68-72 [9065722.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4243-51 [9373234.001]
  • [Cites] Med Pediatr Oncol. 1998 Apr;30(4):233-9 [9473758.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • (PMID = 19841326.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K22 CA113557
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2815999
  •  go-up   go-down


80. Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig WD, Riehm H, Welte K, Schrappe M: Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol; 2006 Dec 20;24(36):5742-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
  • PURPOSE: The role of hematopoietic stem-cell transplantation (SCT) in first complete remission (CR1) for children with very high-risk (VHR) acute lymphoblastic leukemia (ALL) is still under critical discussion.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


81. Asnafi V, Buzyn A, Thomas X, Huguet F, Vey N, Boiron JM, Reman O, Cayuela JM, Lheritier V, Vernant JP, Fiere D, Macintyre E, Dombret H: Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood; 2005 Apr 15;105(8):3072-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study.
  • Patients with T-cell acute lymphoblastic leukemias (T-ALLs) within the Leucemies Aigues Lymphoblastiques de l'Adulte-94 (LALA-94) prospective trial were treated with a 4-drug per 4-week induction, with intermediate-dose cytarabine and mitoxantrone salvage treatment for patients not achieving complete remission (CR) in 1 course.
  • Both TCR and genotypic stratification can therefore contribute to risk-adapted management of adult T-ALLs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cytarabine / administration & dosage. Genotype. Humans. Immunophenotyping. Incidence. Middle Aged. Mitoxantrone / administration & dosage. Prospective Studies. Recurrence. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15637138.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Receptors, Antigen, T-Cell; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


82. Seiter K, Katragadda S, Ponce D, Rasul M, Ahmed N: Temozolomide and cisplatin in relapsed/refractory acute leukemia. J Hematol Oncol; 2009;2:21
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide and cisplatin in relapsed/refractory acute leukemia.
  • Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide.
  • We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia.
  • Fifteen patients had AML, 3 had ALL, and 2 had biphenotypic leukemia.
  • There was one complete remission in this heavily pretreated patient population.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Dacarbazine / analogs & derivatives. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Resistance, Neoplasm / drug effects. Female. Humans. Male. Middle Aged. Recurrence. Salvage Therapy. Treatment Failure. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):735-41 [9816224.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):547-54 [15973664.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2007 Apr;21(4):821-4 [17252015.001]
  • [Cites] DNA Repair (Amst). 2007 Aug 1;6(8):1179-86 [17500047.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2756-60 [17948909.001]
  • [Cites] Anticancer Drugs. 1992 Aug;3(4):401-5 [1421437.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):5846-52 [3664486.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1974 Mar;7(3):529-38 [4824827.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3249-53 [12149298.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Aug;294(2):664-71 [10900246.001]
  • [Cites] Leukemia. 2000 Mar;14(3):476-9 [10720145.001]
  • [Cites] Ann Oncol. 1995 Apr;6(4):389-93 [7619755.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2933-6 [9230204.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Oct;279(1):416-22 [8859021.001]
  • [Cites] Biochem Pharmacol. 1996 May 3;51(9):1221-8 [8645346.001]
  • [Cites] Leukemia. 1995 Nov;9(11):1888-95 [7475280.001]
  • [Cites] J Chemother. 1995 Jun;7(3):224-9 [7562019.001]
  • [Cites] Leukemia. 1995 Jul;9(7):1126-9 [7630183.001]
  • [Cites] Mol Pharmacol. 1998 Aug;54(2):334-41 [9687575.001]
  • (PMID = 19463179.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2694825
  •  go-up   go-down


83. Lee KH, Lee JH, Choi SJ, Lee JH, Seol M, Lee YS, Kim WK, Lee JS, Seo EJ, Jang S, Park CJ, Chi HS: Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia; 2005 Sep;19(9):1509-16
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • Clinical impact of imatinib was evaluated in 20 patients (median age, 37 years; range, 15-67 years) with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), who were administered with induction chemotherapy of daunorubicin, vincristine, prednisolone, and L-asparaginase, along with imatinib 600 mg/day during remission induction and 400 mg/day during consolidation courses.
  • One patient died on day 14 from septic shock, while the remaining 19 achieved complete remission (CR).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Benzamides. Female. Hematopoietic Stem Cell Transplantation. Humans. Imatinib Mesylate. Male. Middle Aged. Prospective Studies. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034462.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


84. Fischer L, Gökbuget N, Schwartz S, Burmeister T, Rieder H, Brüggemann M, Hoelzer D, Thiel E: CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy. Haematologica; 2009 Feb;94(2):224-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy.
  • BACKGROUND: Expression of CD56 has been associated with poor prognosis in acute myeloid leukemia and aggressive lymphoma.
  • DESIGN AND METHODS: We analyzed the impact of CD56 expression in a cohort of 452 newly diagnosed adult T-cell acute lymphoblastic leukemia (T-ALL) patients; clinical data were available for 306 patients.
  • CD56(+) T-ALL were predominantly of non-thymic (pre-T 35%, mature 41%) immunophenotypic subtypes, whereas 53% of the CD56(-) cases were thymic T-ALL (p=0.00002).
  • CONCLUSIONS: CD56 is expressed on a subset of adult T-ALL with distinct immunophenotypical features and higher resistance to therapy.
  • Most CD56(+) ALL were treated in the high-risk arm of the GMALL study protocols owing to their non-thymic phenotype.
  • [MeSH-major] Antigens, CD56. Drug Resistance, Neoplasm. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Female. Humans. Male. Middle Aged. Phenotype. Prognosis. Remission Induction / methods. Survival Analysis. Young Adult


85. Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A, Maertens J, Slavin S, Majolino I, Nagler A, Blaise D, Rocha V, Acute Leukemia Working Party, European Group for Blood and Marrow Transplantation: Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica; 2008 Feb;93(2):303-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.
  • This retrospective study reported the outcome of 97 adult acute lymphoblastic leukemia patients who received a reduced-intensity conditioning allogeneic stem cell transplantation.
  • With a median follow-up of 2.8 years, two year overall-survival, leukemia-free survival and non-relapse mortality were significantly better in patients transplanted in first complete remission (CR1, 52+/-9%; 42+/-10%; and 18+/-7% respectively) compared with those transplanted in more advanced phase (p=0.003, p=0.002 and p=0.01 respectively).
  • In multivariate analysis, disease status (CR1 vs. advanced; p=0.001) and chronic graft-vs-host disease (p=0.01) were associated with an improved overall-survival, suggesting that reduced-intensity conditioning allogeneic stem cell transplantation is feasible in patients with high risk lymphoblastic leukemia in remission at transplantation.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Aged. Chronic Disease. Disease-Free Survival. Europe. Female. Follow-Up Studies. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245655.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


86. Jarfelt M, Fors H, Lannering B, Bjarnason R: Bone mineral density and bone turnover in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol; 2006 Feb;154(2):303-9
MedlinePlus Health Information. consumer health - Osteoporosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone mineral density and bone turnover in young adult survivors of childhood acute lymphoblastic leukaemia.
  • The aim was to study BMD and markers of bone turnover in a well-defined group of survivors of acute lymphoblastic leukaemia (ALL) who had all reached final height as well as peak bone mass, taking both previous treatment and physical activity into consideration.
  • DESIGN: All patients treated for ALL before the onset of puberty in the region of western Sweden, between 1973 and 1985, in first remission were included.

  • MedlinePlus Health Information. consumer health - Bone Density.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452545.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide; 0 / procollagen type I carboxy terminal peptide; 104982-03-8 / Osteocalcin; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


87. Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Lewandowski K, Kielbinski M, Czyz A, Balana-Nowak A, Król M, Skotnicki AB, Jedrzejczak WW, Warzocha K, Lange A, Hellmann A: Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol; 2008 Jun;142(2):227-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
  • The treatment of adults with Philadelphia-negative acute lymphoblastic leukaemia (ALL) depends on the presence of risk factors including age, white blood cell count, immunophenotype and time to complete remission.
  • Patients were treated with a uniform Polish Adult Leukemia Group (PALG) 4-2002 protocol.
  • We conclude that MRD evaluation after induction should be considered with conventional risk criteria for treatment decisions in adult ALL.
  • [MeSH-major] Antigens, CD / analysis. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Cells / immunology. Female. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Male. Middle Aged. Poland. Predictive Value of Tests. Prognosis. Prospective Studies. Recurrence. Risk. Young Adult


88. Chow EJ, Simmons JH, Roth CL, Baker KS, Hoffmeister PA, Sanders JE, Friedman DL: Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation. Biol Blood Marrow Transplant; 2010 Dec;16(12):1674-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation.
  • Survivors of childhood acute lymphoblastic leukemia (ALL) may face an increased risk of metabolic and cardiovascular late effects.
  • To determine the prevalence of and risk factors for adverse cardiometabolic traits in a contemporary cohort of pediatric ALL survivors, we recruited 48 off-therapy patients in remission treated with conventional chemotherapy and 26 treated with total body irradiation (TBI)-based hematopoietic cell transplantation (HCT) in this cross-sectional pilot study.
  • At a median age of 15 years (range, 8-21 years), HCT survivors were significantly more likely than non-HCT survivors to manifest multiple cardiometabolic traits, including central adiposity, hypertension, insulin resistance, and dyslipidemia.
  • Overall, 23.1% of HCT survivors met the criteria for metabolic syndrome (≥ 3 traits), compared with 4.2% of non-HCT survivors (P = .02).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6):1521-5 [15585763.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):81-9 [15994749.001]
  • [Cites] Circulation. 2006 Apr 18;113(15):1888-904 [16618833.001]
  • [Cites] Diabet Med. 2006 May;23(5):469-80 [16681555.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(12):1109-17 [16699534.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4401-7 [16954158.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1765-72 [17047152.001]
  • [Cites] Cardiovasc Res. 2007 Apr 1;74(1):11-8 [17140553.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Aug;29(8):529-34 [17762493.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3816-21 [17652222.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3463-71 [17664354.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2313-20 [17896787.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):160-4 [18206681.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):177-84 [18206686.001]
  • [Cites] J Pediatr. 2008 Feb;152(2):185-90 [18206687.001]
  • [Cites] Diabetes Metab. 2008 Feb;34(1):2-11 [18093861.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Apr;22(2):319-42, viii [18395153.001]
  • [Cites] Bone Marrow Transplant. 2008 May;41(9):797-804 [18195686.001]
  • [Cites] Best Pract Res Clin Haematol. 2008 Jun;21(2):129-38 [18503981.001]
  • [Cites] Br J Haematol. 2008 Jul;142(1):11-26 [18430191.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Nov;69(5):819-27 [18429947.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Nov;30(11):815-22 [18989158.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5537-43 [18809605.001]
  • [Cites] Bone Marrow Transplant. 2009 Jan;43(1):49-54 [18724397.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3698-704 [19564534.001]
  • [Cites] PLoS Genet. 2009 Dec;5(12):e1000768 [20011104.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):170-81 [20056636.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Apr;16(4):515-24 [19961945.001]
  • [Cites] Lancet. 2000 Sep 16;356(9234):993-7 [11041401.001]
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] J Nutr. 2001 Aug;131(8):2184-91 [11481415.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):427-36 [12588201.001]
  • [Cites] Arch Pediatr Adolesc Med. 2003 Aug;157(8):821-7 [12912790.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Feb;26(2):81-90 [14767193.001]
  • [Cites] Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76 [15286277.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3558-62 [15337805.001]
  • [Cites] J Pediatr. 2004 Oct;145(4):439-44 [15480363.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Can J Public Health. 1986 Sep-Oct;77(5):359-62 [3791117.001]
  • [Cites] Am J Epidemiol. 1996 Jun 15;143(12):1219-28 [8651220.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5 [8768873.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1650-6 [9614255.001]
  • [Cites] Transplantation. 2004 Nov 15;78(9):1376-83 [15548978.001]
  • (PMID = 20685399.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024975-01; United States / NCRR NIH HHS / RR / UL1 RR025014-01; United States / NCRR NIH HHS / RR / TL1 RR024978; United States / NCRR NIH HHS / RR / KL2 RR024977; None / None / / UL1 RR025014-01; United States / NCRR NIH HHS / RR / UL1RR025014; United States / NCRR NIH HHS / RR / UL1RR024975; United States / NCRR NIH HHS / RR / UL1 RR025014; United States / NCRR NIH HHS / RR / UL1 RR024975
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ NIHMS211258; NLM/ PMC2975816
  •  go-up   go-down


89. Tobinai K, Takeyama K, Arima F, Aikawa K, Kobayashi T, Hanada S, Kasai M, Ogura M, Sueoka E, Mukai K, Tajima K, Fukuda H, Shirakawa S, Hotta T, Masanori S, Lymphoma Study Group of the Japan Clinical Oncology Group: Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004. Cancer Sci; 2007 Sep;98(9):1350-7
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004.
  • Granulocyte colony-stimulating factor (G-CSF)-supported, post-remission chemotherapy (Cx) for adult acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) was evaluated.
  • For patients achieving complete response (CR), two courses of post-remission Cx (course A of daunorubicin, cytosine arabinoside, vindesine, PSL plus IT-MTX; course B of mitoxantrone, etoposide, vincristine, PSL plus IT-MTX) with the use of G-CSF were repeated alternately; thereafter, maintenance Cx including MTX and 6-mercaptopurine was given for 2 years.
  • Among the 119 patients achieving CR, five died in remission, 76 relapsed, and the remaining 38 were alive without disease.
  • In conclusion, G-CSF-supported, intensive post-remission Cx and subsequent SCT are worthy of further investigation for the treatment of adult ALL and LBL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640299.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


90. Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E: High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemother Pharmacol; 2007 May;59(6):771-9
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
  • OBJECTIVE: High dose (HD) Ara-C combined with a single HD idarubicin dose (IDA) is an efficient and safe salvage regimen for patients with refractory or relapsed acute lymphoblastic leukemia as indicated by phase II studies.
  • PATIENTS AND METHODS: Twenty-five patients with refractory or relapsed acute lymphoblastic leukemia received Ara-C 3 g/m2 from days 1-5, idarubicin (HD-IDA) 40 mg/m2 as rapid intravenous (i.v.) infusion on day 3 and subcutaneous G-CSF 5 microg/kg from day 7 until PMN recovery.
  • RESULTS: Eleven patients (44%, 95% CI: 23-65%) achieved complete remission with median disease free survival for 6 months.
  • Our data do not allow us to clearly attribute this behavior to a pharmacokinetic non-linearity since the baseline creatinine clearance, even within normal values, and patient age are significantly different in the two groups.
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Recurrence. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256136.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


91. He GS, Zhang XH, Yao L, Zhang R, Chen ZX, Wu DP, Sun AN, Jin ZM, Qiu HY, Hu XH: [Acute T cells lymphoblastic leukemia with a t(1;19)(q23;p13) and E2A-PBX1 in an adult: one case report and literature review]. Zhonghua Xue Ye Xue Za Zhi; 2009 Oct;30(10):675-7
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute T cells lymphoblastic leukemia with a t(1;19)(q23;p13) and E2A-PBX1 in an adult: one case report and literature review].
  • OBJECTIVE: To report a case of T cell acute lymphoblastic leukemia (ALL) with t(1;19)(q23;pl3) and E2A-PBX1 fusion gene, which is a characteristic translocation of childhood B cell ALL (B-ALL).
  • The patient was induced with hyper CVAD regimen (cyclophosphamide, vincristine, adriamycin, and dexamethasone), and achieved complete remission with normal cytogenetic karyotype 46 XY[10], and negative E2A-PBX1.
  • CONCLUSION: t(1;19)E2A-PBX1(+) can be implicated in adult T-ALL, besides childhood B-ALL.
  • [MeSH-major] Homeodomain Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Humans. Karyotyping. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954663.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 146150-85-8 / E2A-Pbx1 fusion protein
  •  go-up   go-down


92. Hallböök H, Gustafsson G, Smedmyr B, Söderhäll S, Heyman M, Swedish Adult Acute Lymphocytic Leukemia Group, Swedish Childhood Leukemia Group: Treatment outcome in young adults and children &gt;10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer; 2006 Oct 1;107(7):1551-61
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol.
  • BACKGROUND: Several studies have reported a more favorable outcome for teenagers and young adults with acute lymphoblastic leukemia (ALL) when they were treated in pediatric oncology departments compared with adult hematology departments.
  • METHODS: In Sweden during the 1990s, adolescents with ALL were treated in a pediatric oncology unit or in an adult hematologic unit, depending on the initial referral.
  • In the current national, comparative, retrospective study, patients with ALL aged 10 years to 40 years who were treated either according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL protocol (1992-2000) (NOPHO-92 protocol) or according to the Swedish Adult ALL Group protocol (1994-2000) (Adult protocol) were included.
  • There was a significant difference in the remission rate between the NOPHO-92 protocol (99%; n = 144 patients) and the Adult protocol (90%; n = 99 patients; P < .01), and the event-free survival (EFS) was also superior for the NOPHO-92 protocol compared with the Adult protocol (P < .01).
  • However, EFS was higher for patients aged 15 years to 25 years compared with patients aged 26 years to 40 years within the Adult protocol group (P = .01).
  • CONCLUSIONS: The NOPHO-92 protocol resulted in a better outcome than the Adult protocol; therefore, adolescents may benefit from the pediatric protocol treatment strategy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Prognosis. Survival Analysis. Sweden. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16955505.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Gong H, Liu WL, Zhou JF, Xu HZ: [Expression of mitosis checkpoint gene CHFR in acute leukemia]. Zhonghua Yi Xue Za Zhi; 2005 Apr 27;85(16):1085-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of mitosis checkpoint gene CHFR in acute leukemia].
  • OBJECTIVE: To investigate the expression of mitosis checkpoint gene CHFR in adult patients with acute leukemia (AL) and its clinical significance.
  • METHODS: Four ml of bone marrow was extracted from 65 AL patients, 38 males and 27 females, with the median age of 35, 43 with acute myelocytic leukemia (AML) and 22 with acute lymphocytic leukemia (ALL), 45 de novo patients and 20 recurrent patients, and 8 normal donor of allogeneic bone marrow transplantation as controls.
  • (1) The levels of CHFR protein and mRNA were correlated with the cumulative percentages of cells in S phases. (2) The expression level of CHFR protein in 40.6% (13/32) of the AL patients and that of the CHFR mRNA in 60.0% (27/45) of the AL patients were both significantly lower than those of the normal controls. (3) The mean expression level of CHFR protein in the recurrent acute lymphoblastic leukemia (ALL) was 0.71, significantly higher than that of the de novo group (0.38, t = 2.54, P = 0.017). (4) The complete remission (CR) rates in the AL patients with high expression levels of CHFR protein and mRNA were 30.2% and 42.4% respectively, significantly lower than those in the AL patients with low expression levels (88.6% and 85.4% respectively, both P < 0.05).
  • CONCLUSION: By affecting mitotic checkpoint function, CHFR inactivation plays a key role in tumorigenesis in adult patients with acute leukemia.
  • Moreover, the aberrant expression of CHFR appears to be a good molecular marker to predict the sensitivity of acute leukemia to chemotherapy.
  • [MeSH-major] Cell Cycle Proteins / biosynthesis. Leukemia, Myeloid, Acute / genetics. Neoplasm Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / pharmacology. Cell Cycle. Child. Drug Resistance. Female. HL-60 Cells. Humans. Male. Middle Aged. Mitosis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029562.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CHFR protein, human; 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


94. Asgarian Omran H, Shabani M, Vossough P, Sharifian R, Tabrizi M, Khoshnoodi J, Jeddi-Tehrani M, Rabbani H, Shokri F: Cross-sectional monitoring of Wilms' tumor gene 1 (WT1) expression in Iranian patients with acute lymphoblastic leukemia at diagnosis, relapse and remission. Leuk Lymphoma; 2008 Feb;49(2):281-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-sectional monitoring of Wilms' tumor gene 1 (WT1) expression in Iranian patients with acute lymphoblastic leukemia at diagnosis, relapse and remission.
  • High WT1 mRNA expression has been detected in the majority of acute leukemias and has been identified as a convenient marker for disease monitoring.
  • The aim of this study was to evaluate WT1 expression in Iranian ALL patients at diagnosis, relapse and remission.
  • WT1 mRNA was detected in leukemic cells of ALL patients obtained at diagnosis (n = 62), relapse (n = 19) and remission (n = 35) using a semi-quantitative RT-PCR method.
  • On the basis of the baseline value, leukemic cells from 51.6% (32/62) of the newly diagnosed patients and 57.9% (11/19) of the relapsed patients were WT1 positive; however, all of the patients in remission (35/35) were WT1 negative.
  • WT1 expression in newly diagnosed and relapsed ALL patients was significantly higher than that of the ALL patients at remission and normal subjects (p < 0.0001).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. RNA, Messenger / blood. WT1 Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / blood. Case-Control Studies. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Iran. Male. Neoplasm, Residual. Recurrence. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Wilms' tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Leuk Lymphoma. 2008 Mar;49(3):598. Omran, Hossein [corrected to Asgarian Omran, Hossein]
  • (PMID = 18231915.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / WT1 Proteins
  •  go-up   go-down


95. Sandler ES, Homans A, Mandell L, Amylon M, Wall DA, Devidas M, Buchanan GR, Lipton JM, Billett AL: Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a pediatric oncology group pilot feasibility study. J Pediatr Hematol Oncol; 2006 Apr;28(4):210-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a pediatric oncology group pilot feasibility study.
  • BACKGROUND: Relapsed acute lymphoblastic leukemia (ALL) in children is associated with a poor outcome, especially for those patients whose relapse occurs during the first 36 months after diagnosis.
  • PROCEDURE: Eligible patients with a bone marrow relapse of non-T, non-B ALL underwent a common induction and consolidation followed by receipt of either an allogeneic HSCT from a human leukocyte antigen (HLA)-identical sibling or an autologous HSCT purged with B-4 blocked ricin.
  • Five of them have remained in remission for a median of 78 months.
  • Four have remained in remission for a median of 94 months.
  • Of the nine patients who received alternative donor transplants, only two remain in remission.
  • [MeSH-major] Bone Marrow / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols. Child. Child, Preschool. Female. Humans. Male. Pilot Projects. Recurrence. Treatment Outcome


96. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, Camitta BA: Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia; 2010 Feb;24(2):355-70
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.
  • From 1984 to 2001, the Pediatric Oncology Group (POG) conducted 12 acute lymphoblastic leukemia (ALL) studies.
  • Ten-year event-free survival (EFS) for patients >12 months of age with B-precursor ALL on acute leukemia in children 14, 15 and 16 series were 66.7+/-1.2%, 68.1+/-1.4% and 73.2+/-2.1%, respectively.
  • There was a non-significant improvement in EFS for infants (10-year EFS 17.7+/-7.2-31.9+/-8.3%).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20016527.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA98413; United States / NCI NIH HHS / CA / CA 29139; United States / NCI NIH HHS / CA / U10 CA030969-22; United States / NCI NIH HHS / CA / U10 CA029139-22; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA 30969; United States / NCI NIH HHS / CA / U10 CA029139; United States / NCI NIH HHS / CA / U10 CA098543-07; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA030969; United States / NCI NIH HHS / CA / U10 CA098413-07; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS158683; NLM/ PMC4300959
  •  go-up   go-down


97. Tylavsky FA, Smith K, Surprise H, Garland S, Yan X, McCammon E, Hudson MM, Pui CH, Kaste SC: Nutritional intake of long-term survivors of childhood acute lymphoblastic leukemia: evidence for bone health interventional opportunities. Pediatr Blood Cancer; 2010 Dec 15;55(7):1362-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutritional intake of long-term survivors of childhood acute lymphoblastic leukemia: evidence for bone health interventional opportunities.
  • BACKGROUND: Survivors of childhood acute lymphoblastic leukemia (ALL) are vulnerable to exaggeration of the aging process including decreased bone mineral density (BMD).
  • PROCEDURE: Survivors (n = 164) of childhood ALL who had completed treatment for at least 5 years and were in continuous remission, completed a 110-item food questionnaire that reflected dietary intake over the previous year.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Paediatr Suppl. 1999 Dec;88(433):1-4 [10626537.001]
  • [Cites] J Bone Miner Res. 1994 Apr;9(4):459-63 [8030433.001]
  • [Cites] J Nutr. 2006 Jun;136(6):1453-6 [16702302.001]
  • [Cites] J Pediatr. 2006 Oct;149(4):518-25 [17011325.001]
  • [Cites] Leukemia. 2001 May;15(5):728-34 [11368432.001]
  • [Cites] J Bone Miner Res. 2002 Jul;17(7):1230-6 [12096836.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3494S-3503S [12421876.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2003 Jan;58(1):82-91 [12560417.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] Bone. 2003 Apr;32(4):372-80 [12689680.001]
  • [Cites] Prev Med. 2003 May;36(5):615-23 [12689807.001]
  • [Cites] Adv Data. 2003 Apr 17;(334):1-4 [12743879.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]
  • [Cites] J Nutr. 2003 Nov;133(11):3592-7 [14608079.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1858-63 [15070956.001]
  • [Cites] J Bone Miner Res. 2004 Jul;19(7):1084-91 [15176990.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1969-76 [17035407.001]
  • [Cites] Br J Nutr. 2007 Apr;97(4):661-6 [17349078.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Mar 16;56(10):213-7 [17363889.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1183-9 [17401007.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2313-20 [17896787.001]
  • [Cites] Bone. 2007 Dec;41(6):987-94 [17936100.001]
  • [Cites] Calcif Tissue Int. 2008 Jan;82(1):1-11 [18175033.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):118-22 [18338394.001]
  • [Cites] JAMA. 2008 May 28;299(20):2401-5 [18505949.001]
  • [Cites] Int J Vitam Nutr Res. 2007 Nov;77(6):359-68 [18622945.001]
  • [Cites] Contemp Clin Trials. 2008 Sep;29(5):711-9 [18586578.001]
  • [Cites] J Pediatr. 1995 Jul;127(1):63-7 [7608813.001]
  • [Cites] Prev Med. 1997 Nov-Dec;26(6):808-16 [9388792.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] Int J Cancer Suppl. 1998;11:35-9 [9876475.001]
  • [Cites] Osteoporos Int. 2005 Feb;16(2):163-71 [15185065.001]
  • [Cites] J Bone Miner Res. 2005 Apr;20(4):596-603 [15765178.001]
  • [Cites] J Am Coll Nutr. 2005 Apr;24(2):99-106 [15798076.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):1998-2004 [15671096.001]
  • [Cites] Am J Clin Nutr. 2005 Apr;81(4):923-33 [15817873.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):881-91 [16035086.001]
  • [Cites] J Am Geriatr Soc. 2005 Nov;53(11):1875-80 [16274367.001]
  • [Cites] Ann Pharmacother. 2005 Dec;39(12):2086-90 [16249271.001]
  • [Cites] Am J Epidemiol. 2006 Jan 1;163(1):9-17 [16306312.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] JAMA. 2006 Apr 5;295(13):1549-55 [16595758.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4639-45 [18824710.001]
  • [Cites] J Am Diet Assoc. 2008 Nov;108(11):1854-64 [18954575.001]
  • [Cites] PLoS Med. 2008 Oct 14;5(10):e196 [18922041.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Nov;30(11):815-22 [18989158.001]
  • [Cites] J Pediatr Hematol Oncol. 2009 Apr;31(4):259-66 [19346877.001]
  • [Cites] Joint Bone Spine. 2009 May;76(3):234-40 [19217816.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2339-55 [19364955.001]
  • [Cites] Prev Med. 2009 Aug-Sep;49(2-3):93-8 [19523482.001]
  • [Cites] J Bone Miner Res. 2004 Aug;19(8):1231-40 [15231009.001]
  • [Cites] Am J Clin Nutr. 2004 Oct;80(4):1075-80 [15447922.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Lancet. 1991 Jan 12;337(8733):61-6 [1670723.001]
  • [Cites] Pediatr Radiol. 2000 Aug;30(8):558-65 [10993541.001]
  • (PMID = 20981691.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA-21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium, Dietary; 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ NIHMS214402; NLM/ PMC3586793
  •  go-up   go-down


98. Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M: Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant; 2008 May;14(5):568-75
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
  • We retrospectively evaluated the outcomes of 37 adult patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT) conditioned with medium-dose VP-16 (VP, 30 mg/kg), cyclophosphamide (CY, 120 mg/kg), and fractionated total-body irradiation (TBI, 12 Gy) (medium-dose VP/CY/TBI).
  • Ten patients were Philadelphia chromosome-positive (Ph(+)) and 35 patients were in complete remission (CR) at transplantation.
  • Grade II-III acute graft-versus-host disease (GVHD) and chronic GVHD (cGVHD) occurred in 15 and 18 patients, respectively.
  • No patient developed grade IV acute GVHD (aGVHD) or died of GVHD.
  • Non-CR at transplantation, MRD, and no aGVHD were significant adverse prognostic factors for survival.
  • Medium-dose VP/CY/TBI for adult ALL patients was associated with lower relapse rate and no increase in toxicity, resulting in better survival.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Graft vs Host Disease. Humans. Male. Prognosis. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410899.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


99. Gutierrez-Aguirre CH, Gomez-Almaguer D, Cantu-Rodríguez OG, Gonzalez-Llano O, Jaime-Perez JC, Herena-Perez S, Manzano CA, Estrada-Gomez R, Gonzalez-Carrillo ML, Ruiz-Argüelles GJ: Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study. Bone Marrow Transplant; 2007 Sep;40(6):535-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study.
  • Using non-myeloablative conditioning, allogeneic hematopoietic stem cell transplantation (HSCT) was conducted in 43 ALL patients in a CR2.
  • Ten patients (23%) developed acute GVHD, whereas eight patients (18.6%) developed chronic GVHD.
  • These results are inferior to those obtained using the same allografting method in other leukemias, probably as a consequence of poor susceptibility to the graft-versus-leukemia effect of the ALL cells beyond first remission as compared with other hematological malignancies.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Granulocytes / cytology. Humans. Infant. Leukocyte Count. Male. Middle Aged. Prospective Studies. Recurrence. Remission Induction. Survival Rate. Transplantation, Homologous


100. Brouwer C, Vermunt-de Koning DG, Trueworthy RC, Ter Riet PG, Duley JA, Trijbels FJ, Hoogerbrugge PM, Bökkerink JP, van Wering ER, De Abreu RA: Monitoring of inosine monophosphate dehydrogenase activity in mononuclear cells of children with acute lymphoblastic leukemia: enzymological and clinical aspects. Pediatr Blood Cancer; 2006 Apr;46(4):434-8
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring of inosine monophosphate dehydrogenase activity in mononuclear cells of children with acute lymphoblastic leukemia: enzymological and clinical aspects.
  • IMPDH activities were determined in children who were diagnosed with and treated for acute lymphoblastic leukemia (ALL), and in a group of control children.
  • CONCLUSION: The decrease of IMPDH activity at remission of ALL seems to be at least partly due to the eradication of lymphoblasts with the type 2 isoform of the enzyme.
  • [MeSH-major] IMP Dehydrogenase / metabolism. Leukocytes, Mononuclear / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Enzyme Activation. Female. Humans. Infant. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16333815.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.205 / IMP Dehydrogenase
  •  go-up   go-down






Advertisement